UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DCD.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Quarterly report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the quarterly period ended JuneSeptember 30, 20132020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________

Commission File NumberNumber: 1-9927

COMPREHENSIVE CARE CORPORATION

(Exact name of registrant as specified in its charter)

 

ADVANZEON SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)

Delaware 95-2594724

(State or other jurisdiction of

incorporation or organization)

 

(IRSI.R.S. Employer

Identification No.)

3405 W. Dr. Martin Luther King Jr. Blvd, Suite 101, Tampa, FL 33607

2901 W. Busch Blvd. Suite 701  
Tampa, FL

33618
(Address of principal executive offices)(Zip Code)

(Address of principal executive offices and zip code)

813-517-8484
(Registrant’s telephone number, including area code)

(813) 288-4808

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

 

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant:registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingfling requirements for the past 90 days. Yesx ☒ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesx No ¨

Indicate by check mark whether the Registrantregistrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.filer, smaller reporting company, or an emerging growth company. See definitionthe definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company,” and large accelerated filer”“emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐Accelerated filer ☐
Large Accelerated FilerNon-accelerated filer ¨Accelerated Filer¨
Non-Accelerated Filer¨Smaller reporting company 
xEmerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrantregistrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 9, 2013, there were 62,887,902September 15, 2021, the registrant had outstanding 119,907,316 shares of the registrant’s common stock,its $0.01 par value outstanding.Common Stock.

 

ADVANZEON SOLUTIONS, INC

 


COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

TABLETABLE OF CONTENTS CONTENTS

  

Pages
PART I.Financial Information
  PAGE
Item 1.Consolidated Financial Statements 

PART I – FINANCIAL INFORMATION

ITEM 1 – CONSOLIDATED FINANCIAL STATEMENTS

 

Consolidated Balance Sheets as of JuneSeptember 30, 20132020 (unaudited) and December 31, 20122019

3
  3
 

Consolidated Statements of Operations for the three monthsThree and six months ended JuneNine-Month Periods Ended September 30, 20132020 and 20122019 (unaudited)

4
  4
Consolidated Statement of Stockholders' Deficiency For the Three and Nine-Month Periods Ended September 30, 2020 and 2019 (unaudited)5
 

Consolidated Statements of Cash Flows for the six months ended JuneNine-Month Periods Ended September 30, 20132020 and 20122019 (unaudited)

6
  5
 

Notes to Consolidated Financial Statements

7
  
6-13Item 2.Management‘s Discussion and Analysis of Financial Condition and Results of Operations17
 
Item 3.Quantitative and Qualitative Disclosure about Market Risk

ITEM 2 – MANAGEMENTS DISCUSSIONAND ANALYSISOF FINANCIAL CONDITIONAND RESULTSOF OPERATIONS

  
14-22Item 4.Controls and Procedures
 
PART II.Other Information

ITEM 3 – QUANTITATIVEAND QUALITATIVE DISCLOSURESABOUT MARKET RISK

  
22Item 1.Legal Proceedings24
 
Item 1A.Risk Factors24

ITEM 4 – CONTROLSAND PROCEDURES

  
22Item 2.Unregistered Sales of Equity Securities and Use of Proceeds24
 
Item 3.Default upon Senior Securities30

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

  
22-23Item 4.Mine Safety 30
 
Item 5.Other Information31

ITEM 1A – RISK FACTORS

  
23Item 6.Exhibits 

ITEM 2 – UNREGISTERED SALESOF EQUITY SECURITIESAND USEOF PROCEEDS

23-24

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

24

ITEM 4 – MINE SAFETY DISCLOSURES

24

ITEM 5 – OTHER INFORMATION

24

ITEM 6 – EXHIBITS

25

SIGNATURES

26

CERTIFICATIONS

31

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

PART I – FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

ADVANZEON SOLUTIONS, INC. ( PARENT COMPANY DEBTOR-IN-POSSESSION)

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)September 30, 2020 (unaudited) and December 31, 2019

 

   June 30,
2013
  December 31,
2012
 
   (Unaudited)    

ASSETS

   

Current assets:

   

Cash

  $1,245   $920  

Accounts receivable

   850    4,546  

Other

   648    181  
  

 

 

  

 

 

 
   2,743    5,647  

Property and equipment, net

   107    172  

Other

   221    305  
  

 

 

  

 

 

 
  $3,071   $6,124  
  

 

 

  

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY DEFICIENCY

   

Current liabilities:

   

Notes payable:

   

Related parties

  $2,000   $2,000  

Other

   2,996    2,239  

Current portion of long-term debt, including $1,000 to related parties

   4,005    3,067  

Accounts payable

   1,001    1,110  

Accrued claims payable

   11,650    13,099  

Other accrued expenses

   6,407    5,820  
  

 

 

  

 

 

 
   28,059    27,335  

Long-term debt, net of current portion

   249    1,732  
  

 

 

  

 

 

 

Total liabilities

   28,308    29,067  
  

 

 

  

 

 

 

Stockholders’ equity deficiency:

   

Preferred stock, $50.00 par value, noncumulative:

   

Series C Convertible, 14,400 shares authorized; 10,434 shares issued and outstanding

   522    522  

Series D Convertible; 7,000 shares authorized; 250 shares issued and outstanding; none vested

   —      —    

Other series; 974,260 shares authorized; none issued

   —      —    

Common stock, $0.01 par value; authorized: 500,000,000 shares; issued and outstanding: 62,316,502 and 59,451,836 shares

   623    594  

Additional paid-in capital

   26,713    25,982  

Deficit

   (53,095  (50,041
  

 

 

  

 

 

 

Total stockholders’ equity deficiency

   (25,237  (22,943
  

 

 

  

 

 

 
  $3,071   $6,124  
  

 

 

  

 

 

 
  September 30, 2020 December 31,
  (unaudited) 2019
ASSETS        
CURRENT ASSETS        
Cash $35,566  $69,327 
Restricted cash  845,340    
Accounts receivable  60,302   29,769 
Current portion of right of use asset  137,992   113,911 
Other current assets  516,238   978,860 
Total current assets  1,595,438   1,191,867 
         
PROPERTY, PLANT, AND EQUIPMENT        
Property and equipment, net  5,372   1,239 
Leasehold improvements, net      
Total property, plant, and equipment  5,372   1,239 
         
RIGHT OF USE ASSET, NET OF CURRENT PORTION  144,886   146,880 
         
TOTAL ASSETS $1,745,696  $1,339,986 
         
CURRENT LIABILITIES        
Related party loans payable $147,761  $342,670 
Account payable  538,113   251,704 
Debt  10,422,356   12,352,189 
Contingent liability  642,660   642,659 
Current portion of lease liability  137,992   113,911 
Other accrued expenses  14,093,492   15,891,787 
Total current liabilities  25,982,374   29,594,920 
         
LEASE LIABILITY, NET OF CURRENT PORTION  144,886   146,880 
         
TOTAL LIABILITIES  26,127,260   29,741,800 
         
STOCKHOLDERS’ DEFICIENCY        
Preferred stock, $.001 par value; 1,000,000 shares authorized as of September 30, 2020 and December 31, 2019      
Series C Convertible Preferred; $.001 par value; 14,400 shares authorized; 14,400 shares issued and outstanding as of September 30, 2020 and December 31, 2019  10   10 
Series D Convertible Preferred; $.001 par value; 7,000 shares authorized; 250 shares issued and outstanding as of September 30, 2020 and December 31, 2019      
         
Remaining Preferred stock; $.001 par value; 978,600 shares authorized as of September 30, 2020 and December 31, 2019      
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 13,201,582 shares reserved; 117,516,838 and 71,661,656 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively  1,175,168   716,617 
Additional paid in capital  35,438,520   28,719,246 
Accumulated deficit  (60,995,262)  (57,837,687)
Total stockholders’ deficiency  (24,381,564)  (28,401,814)
         
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY $1,745,696  $1,339,986 

See

The accompanying notes toare an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC. ( PARENT COMPANY DEBTOR-IN-POSSESSION)

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Amounts in thousands, except per share amounts)For the Three and Nine-Month Periods Ended September 30, 2020 and 2019 (unaudited)

  Three-Month Period Ended Nine-Month Period Ended
  September 30, September 30,
  2020 2019 2020 2019
         
Revenues:                
Obstructive sleep apnea (OSA) $127,070   68,173   358,062   226,549 
Total revenues  127,070   68,173   358,062   226,549 
                 
Costs and expenses:                
Costs of revenues  69,599   2,394   199,508   110,211 
General and administrative  620,126   428,077   1,931,591   1,269,920 
Depreciation and amortization  311   84   934   524 
Total costs and expenses  690,036   430,555   2,132,033   1,380,655 
                 
Loss from operations  (562,966)  (362,382)  (1,773,971)  (1,154,106)
                 
Other income (expense):                
Interest expense  (291,258)  (383,798)  (1,393,659)  (1,052,991)
Interest income  34   29   53   6,023 
Legal settlement           112,172 
State Tax Penalty     (1,650)     (1,650)
Forgivable SBA EIBL loan advance        10,000    
Total other expense  (291,224)  (385,419)  (1,383,606)  (936,446)
                 
Net loss $(854,190)  (747,801)  (3,157,577)  (2,090,552)
                 
PER SHARE INFORMATION                
Net Loss Per Common Share $(0.01)  (0.01)  (0.03)  (0.03)
                 
Weighted Average Number of Common                
Shares Outstanding  115,989,853   67,361,656   86,852,188   67,027,954 

 

   Three Months Ended  Six Months Ended 
   June 30,  June 30, 
   2013  2012  2013  2012 

Managed care revenues

  $1,078   $18,124   $2,295   $36,014  
  

 

 

  

 

 

  

 

 

  

 

 

 

Costs and expenses:

     

Costs of revenues

   682    13,765    1,471    30,409  

General and administrative

   1,488    2,226    2,879    2,741  

Depreciation and amortization

   24    60    64    156  
  

 

 

  

 

 

  

 

 

  

 

 

 
   2,194    16,051    4,414    33,306  
  

 

 

  

 

 

  

 

 

  

 

 

 

Operating income (loss)

   (1,116  2,073    (2,119  2,708  

Other income (expense):

     

Interest expense, including amortization of debt discount of $41, $75, $89, and $270

   (533  (465  (934  (1,028

Other non-operating income, net

   4    1    4    12  
  

 

 

  

 

 

  

 

 

  

 

 

 

(Loss) income before income taxes

   (1,645  1,609    (3,049  1,692  

Income taxes

   2    2    5    5  
  

 

 

  

 

 

  

 

 

  

 

 

 

Net income (loss)

  $(1.647 $1,607   $(3,054 $1,687  
  

 

 

  

 

 

  

 

 

  

 

 

 

Net income (loss) attributable to common stockholders

  $(1,647 $1,607   $(3,054 $1,687  
  

 

 

  

 

 

  

 

 

  

 

 

 

(Loss) earnings per common share:

     

Basic

  $(0.03 $0.03   $(0.05 $0.03  
  

 

 

  

 

 

  

 

 

  

 

 

 

Diluted

   n/a   $0.02    n/a   $0.02  
   

 

 

   

 

 

 

Weighted average common shares outstanding:

     

Basic

   61,102    59,252    60,427    59,252  
  

 

 

  

 

 

  

 

 

  

 

 

 

Diluted

   n/a    88,434    n/a    81,787  
   

 

 

   

 

 

 

SeeThe accompanying notes toare an integral part of these consolidated financial statements.

4

ADVANZEON SOLUTIONS, INC. ( PARENT COMPANY DEBTOR-IN-POSSESSION)

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

  Series C convertible Preferred Stock Number of Shares Series C Convertible Preferred Stock Amount Common Stock Number of Shares Common Stock Amount Additional Paid - in Capital Accumulated Deficit Total
Balance at December 31, 2018  10,434  $10   66,661,656  $666,617  $28,012,007  $(54,581,873) $(25,903,239)
Stock Issued for Services        200,000   2,000   14,000      16,000 
Sale of Stock        500,000   5,000   10,000      15,000 
Net Loss                 (727,761)  (727,761)
Balance at March 31, 2019  10,434   10   67,361,656   673,617   28,036,007   (55,309,634)  (26,600,000)
Stock Issued for Services                     
Sale of Stock                     
Net Loss                 (614,990)  (614,990)
Balance at June 30, 2019  10,434   10   67,361,656   673,617   28,036,007   (55,924,624)  (27,214,990)
Stock Issued for Services                     
Sale of Stock                     
Net Loss                 (747,801)  (747,801)
Balance at September 30, 2019  10,434   10   67,361,656   673,617   28,036,007   (56,672,425)  (27,962,791)
Stock Issued for Services        4,300,000   43,000   430,000      473,000 
Sale of Warrants              253,239      253,239 
Sale of Stock                     
Net Loss                 (1,165,262)  (1,165,262)
Balance at December 31, 2019  10,434   10   71,661,656   716,617   28,719,246   (57,837,687)  (28,401,814)
Stock Issued for Services                     
Sale of Warrants                     
Sale of Stock                     
Net Loss                 (928,346)  (928,346)
Balance at March 31, 2020  10,434   10   71,661,656   716,617   28,719,246   (58,766,033)  (29,330,160)
Stock Issued for Services                     
Sale of Warrants              18,251      18,251 
Sale of Stock        45,089,783   450,897   6,624,483      7,075,380 
Net Loss                  (1,375,039)  (1,375,039)
Balance at June 30, 2020  10,434   10   116,751,439   1,167,514   35,361,980   (60,141,072)  (23,611,568)
Stock Issued for Services                     
Sale of Warrants                     
Sale of Stock        765,399   7,654   76,540      84,194 
Net Loss                  (854,190)  (854,190)
Balance at September 30, 2020  10,434   10   117,516,838   1,175,168   35,438,520   (60,995,262)  (24,381,564)

The accompanying notes are an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC. ( PARENT COMPANY DEBTOR-IN-POSSESSION)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Amounts in thousands)For the Nine-Month Periods Ended September 30, 2020 and 2019 (unaudited)

 

   Six Months Ended 
   June 30, 
   2013  2012 

Cash flows from operating activities:

   

Net cash provided by operating activities

  $44   $812  

Cash flows from investing activities:

   

Additions to property and equipment

   —      (2
  

 

 

  

 

 

 

Net cash used in investing activities

   —      (2
  

 

 

  

 

 

 

Cash flows from financing activities:

   

Proceeds from borrowings

   —      100  

Debt issuance costs

   —      (8

Net receipt from revolving credit arrangement

   855    —    

Repayment of debt, including $50 to related parties in 2012

   (574  (243
  

 

 

  

 

 

 

Net cash provided by (used in) financing activities

   281    (151
  

 

 

  

 

 

 

Net increase in cash

   325    659  

Cash at beginning of period

   920    832  
  

 

 

  

 

 

 

Cash at end of period

  $1,245   $1,491  
  

 

 

  

 

 

 

Supplemental disclosures of cash flow information:

   

Cash paid for:

   

Interest

   334    405  
  

 

 

  

 

 

 
  2020 2019
  (unaudited)  
CASH FLOWS FROM OPERATING ACTIVITIES        
Net income (loss) $(3,157,577) $(2,090,552)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:        
Accounts Receivable  (30,534)  (281)
Miscellaneous Receivable  (8,859)  0 
Right of Use Current Portion  (24,081)  (124,311)
Capitalized Portion of Lease  857   857 
Lease Deposit  0   10,000 
Prepaid Expenses  310,006   (68,145)
Loans to Others  8,827   (22,459)
Accrued Interest Receivable  5   0 
Accounts Payable  1,697,035   (722,89)
Lease Liability Current Portion  24,081   124,311 
Payroll Tax Liability  14,771   799 
Accrued Expenses  (1,828,063)  1,118,572 
Contingent Liability  0   0 
Loans Payable Related Party  (194,909)  (292,102)
Loans Payable Related Party: Howard Jenkins  0   0 
Notes Payable  (3,173,673)  2,075,250 
Lease Liability Net of Current  (1,993)  171,885 
Net cash provided by (used in) operating activities  (6,364,107)  180,932 
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Equipment  (5,067)  (1,549)
Depreciation & Amortization  934   524 
Right of Use Asset Net of Current  1,993   (171,886)
Net cash used in investing activities  (2,140)  (172,911)
         
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Preferred Stock  0   0 
Common Stock  458,551   7,000 
Additional Paid in Capital  6,701,023   24,000 
APIC Warrants Outstanding  18,251     
Net cash (used in) provided by financing activities  7,177,825   31,000 
         
  Net (decrease) / increase in cash  811,578   39,021 
         
Cash - Beginning of Year  69,328   25,036 
         
CASH - END OF PERIOD $880,906  $64,057 
         
Supplemental disclosures of cash flow information:        
Cash paid during the year for:        
Interest      
Income taxes      
         
Schedule of non-cash investing transactions:   Convertible promissory note converted to common stock  0  $0 

See

The accompanying notes toare an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC. ( PARENT COMPANY DEBTOR-IN-POSSESSION)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

COMPREHENSIVE CARE CORPORATION1. DESCRIPTION OF THE COMPANY’S BUSINESS AND SUBSIDIARIESBASIS OF PRESENTATION

NOTE 1 – DESCRIPTIONOFTHE COMPANYS BUSINESSAND BASISOF PRESENTATION

The accompanying unaudited interim consolidated financial statements for Comprehensive Care Corporation (referred to herein as the “Company,” or “CompCare”) and its subsidiaries have been prepared in accordance with the Securities and Exchange Commission (“SEC”) rules for interim financial information and do not include all information and notes required for annual financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results for the current periods are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the notes thereto in our most recent annual report on Form 10-K. Our consolidated financial statements include the accounts of the CompanyAdvanzeon Solutions, Inc and our wholly-owned subsidiaries, each with theirits wholly owned subsidiary, and its respective wholly-owned subsidiaries (collectively referred to herein as, “we,”the “Company” ,”Advanzeon” ,”we”, “us” or “our”).

On September 4, 2020, in a matter entitled Dr. Jerry Katzman v. Comprehensive Care Corporation n/k/a/ Advanzeon Solutions, Inc. a receiver was appointed for Advanzeon Solution, Inc. ( the “Company”). The order granting the Plaintiff’s motion for appointment of a receiver was issued in the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County Florida, Case number 12-002570-Division L. The name of the receiver is Burton W. Wiand.

On September 7, 2020, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, Case number 8:20-bk-6764. Also, on September 7, 2020, the Company filed a Notice of Case Under Chapter 11 of the United States Bankruptcy Code and Notice of Automatic Stay with the Circuit Court of the 13th Judicial District in and for Hillsborough County, Florida.

The Company will continue to operate its business as “debtor-in possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court.

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the Company’s financial position as of December 31, 2019, the changes therein for the three and nine-month periods then ended and the results of operations for the three and nine-month periods ended September 30, 2020 and 2019.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019, filed April 9, 2020. The results of operations for the three and nine-month periods ended September 30, 2020 and 2019 are not necessarily indicative of operating results for the full year.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc., and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

We provide managed care services

Use of Estimates- The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the behavioral health, substance abuse,determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and pharmacy management fields for commercial, Medicare, Medicaid and Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies, unions, and Taft-Hartley health and welfare funds. Our managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. Thebeneficial conversion features.

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer base for our services includes both private and governmental entities. Our services are provided by unrelated vendorscredit is generally extended on a subcontract basis.

We assume the financial risk for the costs of member behavioral healthcare services under at-risk contracts in exchange for a fixed, per member per month fee. We may also manage behavioral healthcare programs or perform various managed care functions, such as clinical care management, provider network development and claims processing without assuming financial risk for member behavioral healthcare costs under administrative services only (“ASO”) contracts. In addition, we manage pharmaceutical services for the members of health plans on either an at-risk or ASO basis. In general, our contracts with our other customers have one-year or two-year initial terms, with automatic annual extensions, but they generally provide for cancellation by either party upon 60 to 90 days written notice or, under certain circumstances, the right to request a renegotiation of terms.

NOTE 2 – ACCOUNTS RECEIVABLE

Ourshort-term basis, accounts receivable at June 30, 2013,does not bear interest and December 31, 2012, are concentrateduncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in one account relatedthe event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a major contract in Puerto Ricocase-by-case basis. The maximum losses that expired December 31, 2012.the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Outside Service Company - During the six months ended June 30, 2013, we collected approximately $2.9 millionapplicable period, the Company, from our Puerto Rico client.time to time, utilized the services of Administrative Service Company, Inc., an independent corporate entity, for purposes of paying its account payables, including payroll. The remaining receivable balance was further reduced by approximately $0.8 millionCEO of claims payments made on our behalf by the Puerto Rico client.Company also served as President of Administrative Service Company, Inc. No fees were paid to Administrative Service Company, nor its principals, officers or directors. Administrative Service Company accounts to the Company, monthly, for all funds it receives and disburses.

Pursuant to an Assignment agreement executed April 10, 2013 and effective March 15, 2013,

Revenue Recognition - In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, “Revenue from Contracts with Customers”, the receivable, then totaling $1.3 million, from our former Puerto Rico client was assigned to a creditor (Note 3).

NOTE 3 – NOTES PAYABLE

In April 2013, a 14%, $100,000 convertible note matured and was renewed on the same terms until July 31, 2013 at which time the note was again renewed. The new note utilizes the same terms as the previous note and has a maturity date of October 31, 2013.

In May 2013, a zero-coupon note in the amount of $230,000 matured and was replaced by a new note of similar terms with the same face value and a maturity date of August 31, 2013.

On March 15, 2013, we executed an agreement with a creditor to modifyCompany recognizes revenue when obligations under the terms of a previously matured but unpaid note for $1.4 million. Under such modified terms, the maturity date was extended to January 31, 2014 and the conversion price per common share was reduced to $0.125. In addition, the exercise price per common share of a warrant issued in conjunctioncontract with the note was reset to $0.22. We also assigned a customer receivable from our former Puerto Rico client and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor of $625,000 and a $75,000 loan from an individual related to the creditor. The modification was accounted for as a troubled debt restructuring, but we recognized no gain because the effective interest rateare satisfied. Generally, this occurs upon shipment of the modified promissory note wasCPAP to their customer or when the test is performed.

Property and Equipment - Property and equipment (Note 4) is stated at cost less thanaccumulated depreciation. Depreciation and amortization are computed using the effective interest ratestraight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement (Note 5) is stated at cost less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold improvements are amortized over the shorter of the original promissory note.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

lease term or the asset’s useful life.

 

On May 8, 2013, by agreement with the creditor, the maturity date of the $625,000 loan was extended to July 15, 2013, the conversion price per common share was reduced to $0.125, and the exercise price per common share of a warrant issued in conjunction with the note was likewise decreased $0.22. However, the note was not repaid on its July 15, 2013 due date and is currently the subject of ongoing resolution negotiations. The $75,000 loan from the creditor-related individual was repaid on May 6, 2013.

In addition, we were unable to repay our 14% senior promissory notes of approximately $1.8 million on their maturity date of April 15, 2013. However, prior to June 30, 2013, we completed agreements to extend the maturity date to April 15, 2014, for approximately $1.7 million of the notes. We are currently in negotiations with the remaining holders.

On May 3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. On the closing date, our current maximum allowable amount to borrow was $1,000,000. Increased borrowing amounts above the $1 million are subject to the sole and absolute discretion of the lender. Our initial draw on the credit facility occurred May 3, 2013 in the amount of approximately $884,000, which represents an initial draw of $1 million less transaction expenses. As of August 8, 2013, our current outstanding balance on the credit facility is approximately $800,000 and there is currently no availability to draw additional funds on the credit facility. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, with the exception of our Puerto Rico subsidiary. Borrowings under the credit facility will bear interest at an annual rate of 12%, payable weekly. The credit facility will mature on November 3, 2013. The Agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciation and amortization expenses, and loan-to-value ratio. The Agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default.

Loans under the credit facility will be evidenced by a Revolving Convertible Promissory Note. In the event of a default by the Company, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the Note into shares of our common stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date. The Note or any portion thereof may also be converted in a likewise manner with the consent of the Company.

As consideration for investment banking and advisory services provided to us by the lender, we paid a fee to the lender in the form of 1,470,588 restricted shares of our common stock, which in accordance with the terms of the Agreement, was equivalent to $125,000. The Agreement specifies that if the lender has not realized $125,000 in cash proceeds from the sale of the shares within one year following the Agreement date, we will issue to the lender additional shares of our common stock such that upon lender’s sale of such additional shares, lender may realize $125,000 in cash proceeds. Alternatively, one year after the Agreement date, the lender may require us to redeem any shares that remain in its possession for cash equal to $125,000 less proceeds realized by the lender on previous sales of shares of our common stock. Should the lender realize $125,000 of proceeds without selling all shares, the remaining shares will be returned to us.

The ability of the lender, at its sole discretion, to redeem all or a portion of the shares constitutes a put option. Although the put option is not eligible for settlement until one year after the Agreement date, if it were settled as of June 30, 2013, it would require us to pay the lender $125,000. The following settlement amounts would result from $.01 changes in our stock price below and above the $0.085 per share price at which the initial quantity of shares were issue to the lender, assuming settlement after one year:

Stock price   Additional funds due lender   (Shares due borrower)
Shares  due lender
 
$0.115     n/a     (383,635
$0.105     n/a     (280,114
$0.095     n/a     (154,800
$0.085     n/a     n/a  
$0.075    $14,706     196,080  
$0.065    $29,412     452,492  
$0.055    $44,118     802,145  

In the foregoing table, at a stock price of $.075 and below, the lender would receive cash or additional shares of stock, but not both.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

The maximum amount that we potentially would be required to pay to redeem the shares issued to the lender is $125,000.

We were also unable to repay a $1 million loan from a related party when due May 8, 2013.

In July 2013, a 10%, $50,000 promissory note that had matured May 31, 2013 was repaid.

NOTE 4 LONG TERM DEBT

In June 2013, a 14%, $100,000 note payable matured and was renewed with the same terms until December 2014.

As of June 30, 2013, we were in payment default of $140,000 in principal related to a promissory note requiring monthly $10,000 principal reductions. The note holder has not provided the Company with formal notice of default.

NOTE 5 CONTINGENCIES

Going concern uncertainty:

At June 30, 2013, we had a working capital deficiency of approximately $25.3 million and a stockholders’ equity deficiency of approximately $25.2 million resulting primarily from a history of operating losses and costs of capital. As of June 30, 2013, past due principal and interest totaled approximately $6.0 million, of which $4.7 million was owed to a related party who had not provided the Company with formal notice of default. As a result of these conditions, our ability to continue as a going concern will be dependent upon the success of management’s plans, as set forth in the following paragraph, and is subject to significant uncertainty. Except for consideration in determining the valuation allowance for deferred tax assets from net operating loss carryforwards (Note 8), the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.

Additional Financing

Although our existing capital may not be sufficient to meet our cash needs, we expect to be able to sustain current operations over the near term with our new Senior Secured Revolving Credit Facility, existing customer contracts, the addition of new pharmacy management contracts that we are close to obtaining through our marketing efforts, the collection of receivables, and the extension of vendor payments. However, we will need additional financing in the future and we will continue to explore various alternative sources of financing. Nevertheless, there can be no assurance that we will be able to find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. Our ability to achieve our business objectives and continue as a going concern for a reasonable period of time is dependent upon the success of our plans.

Concentration, major customer contract:

We currently provide behavioral health services on an at-risk basis to approximately 37,000 members of a health plan providing Medicare benefits. This contract accounted for 46.0%, or approximately $1.0 million, of our revenue for the six months ended June 30, 2013. This contract is for a three-year period effective January 1, 2012, and may be terminated by either party with 90 days written notice.

Legal matters:

Aside from the litigation described below, as of the date of this report, we are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results.

(1)

We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr. Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr. Katzman breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr. Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr. Katzman was not entitled to damages. On defendant’s motion to

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr. Katzman damages of approximately $1.3 million. The Company appealed the lower court’s decision and posted a collateralized appeal bond for approximately $1.3 million. On February 14, 2013, the 11th Circuit Court of Appeals of the State of Florida reversed the lower court’s judgment in favor of Katzman and remanded the case for a new trial on both liability and damages. The appellate court also taxed appellate costs in favor of CompCare against Katzman in the amount of $76,554. The decision of the appellate court also reverses the lower court’s award of attorney’s fees previously awarded to Katzman against CompCare and the need for us to maintain an appeal bond for approximately $1.3 million.

(2)On March 2, 2012, a former health plan client in Missouri instituted an arbitration proceeding against us relating to allegations that we breached our obligation to pay claims submitted to us for payment. The amount demanded is approximately $2 million. We have filed a counter claim for breach of contract and tortious interference in an amount between $500,000 and $1 million. The parties have now completed document production. We intend to vigorously defend against the claims asserted in the arbitration demand.

(3)

On February 7, 2011, a health care provider, Oceans Healthcare, LLC, filed suit in the 19th Judicial District Court for the state of Louisiana claiming breach of contract in that we failed to pay claims submitted to us for payment. On January 14, 2013, the Court granted a motion to add six additional plaintiffs to the Oceans suit. The parties are demanding in excess of $2 million. The litigation is currently in the discovery stage. We intend to vigorously defend against the litigation.

(4)On May 30, 2013, a former health plan client in Michigan instituted an arbitration proceeding against us relating to its allegations that we breached our obligation to pay claims submitted to us for payment. The amount demanded is in excess of $5 million. The parties are in the process of selecting an arbitrator to hear the dispute. We intend to vigorously defend against the claims asserted in the arbitration demand.

(5)On August 10, 2012, we filed an arbitration demand against a former client in Puerto Rico. The Company believes that it is owed approximately $2.0 million. A hearing date is currently scheduled in October 2013.

Management believes that it has established a provision for legal expenses that it believes is adequate for the estimated probable minimum losses, including legal defense costs, to be incurred from these matters.

NOTE 6 – FAIRVALUEOFFINANCIALINSTRUMENTS

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in generally accepted accounting principles,GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see Note 7 below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of these financial instruments (all are liabilities)the attached warrants at JuneSeptember 30, 2013,2020 and December 31, 2019 are as follows (in thousands):follows:

 

   Carrying  Estimated 
   Amount  Fair Value 

Notes Payable

  $2,705   $2,660  

Zero-coupon notes

   230    224  

Debentures

   537    479  

Senior notes

   1,771    1,761  

Long-term notes

   225    221  

Less unamortized discount

   (150  —    
  

 

 

  

 

 

 

Net liabilities

  $5,318   $5,345  
  

 

 

  

 

 

 
  September 30, 2020 December 31, 2019
    Estimated   Estimated
    Fair Value of   Fair Value of
  Carrying Attached Carrying Attached
  Amount Warrants Amount Warrants
         
Convertible promissory notes $5,962,713  $  $7,564,173  $ 
Short term notes payable  3,215,803      4,788,016    
Loan payable related party  147,761      342,670    
PPP Loan  1,243,840          
  $10,570,117  $  $12,694,859  $ 

Due

During the nine-month period ended September 30, 2020, there have been 12 additional convertible notes issued totaling $628,540. During the nine-month period ended September 30, 2020, 56 convertible notes totaling $3,802,213 plus accrued interest was converted to the inherent nature of related party transactions, we have not attempted to estimate the fair value of liabilities payable to related parties of the Company. As such, related party notes payable with a carrying value of $3,000,000 are excluded from the table above.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

stock.

 

We may be obligated to issue shares under a redemption provision within the Revolving Credit Facility (see Note 3). The redemption provision constitutes a put option for which we calculated a fair value at the issuanceCost of the Revolving Credit FacilityRevenues - Costs of services consist of supplies and recorded the value as a component of other accrued expenses on our balance sheet. We valued the put option using the Black Scholes options pricing model, a level 3 input, using a risk free interest rate, estimated volatility of our stock price, an estimated term, and expected dividend yield. At each reporting date, we revalue the put option using the same pricing model.

NOTE 7 – EQUITY INSTRUMENTS

Our Series C preferred stock is currently convertible into common stock at the rate of approximately 316.28 common shares for each share of Series C preferred, adjustable for any dilutive issuances of common occurringoperating expenses. Supplies are recognized in the future. Series C preferred shares vote withperiod in which a patient receives the common stockholders on an as-converted basis. The shares are nonparticipating except that dividends, when declared by our Board of Directors on the common stock, must be paid on the Series C stock on an as-converted basis before any dividends are paid on our common stock. The Series C is also cumulative with respect to dividends on common stock and junior series of preferred stock. Other significant rights and preferences of the Series C preferred include:supplies.

 

Right of Use Assets and Lease Liabilities- During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to voteuse the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a separate class to appoint five directorsstraight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the Company, and

liquidation preferences, whereby the Series C holders have a claim against our assets senior to the claim of the holders of our common stock in the event of our liquidation, dissolution or winding-up (thepresent value of the liquidation preference is $250 per share, or approximately $2.6 million at June 30, 2013).

We also have a class of convertible preferred stock, Series D,leases. See Notes 10 and 11 within the financial statement for which 7,000 shares are authorized and 250 shares were issued and outstanding as of June 30, 2013. The shares, which were granted in January 2012, do not vest until the tenth anniversary of the grant date. Such shares were issued in exchange for the cancelation of 120 previously granted warrants to purchase Series D shares. Once vested, a Series D preferred share will be convertible at any time into 100,000 shares of common stock, subject to adjustment in the event of any common stock dividend, split, combination thereof or other similar recapitalization, without additional consideration. Prior to vesting and thereafter, each Series D convertible preferred share is entitled to all voting, dividend, liquidation and other rights accorded a share of Series D convertible preferred stock. As to dividends, the Series D stock is noncumulative. If a dividend is declareddisclosure on the common stock, each share of Series D stock is entitled to receive a dividend equal to 50% of the dividend declared for the common stock as if the Series D stock had been converted. Despite their nonvested status, voting rights of each share nevertheless consist of the right to cast the number of votes equal to those of 500,000 shares of common stock. Unless otherwise required by applicable law, holders of shares of Series D have the right to vote together with holders of common stock as a single class on all matters submitted to a vote of our stockholders. At June 30, 3013, approximately $3.2 million of compensation expense remained to be recognized over the next 8.5 years related to the Series D shares.

We may periodically issue shares of common stock as payment for services, interest and debt. During the six months ended June 30, 2013, we issued approximately 2.9 million shares of common stock to consultants, vendors, and creditors in lieu of cash payment.

Our common stock activity for the six months ended June 30, 2013 and 2012 is summarized below:

   Share
Quantity
2013
   Share Value
($)
   Share
Quantity
2012
   Share Value
($)

Shares outstanding, January 1,

   59,451,836       59,251,836    

Shares issued as compensation for services

   425,000    $83,805      

Shares issued in connection with Revolving Credit Facility

   1,470,588    $125,000      

Shares issued as payment for interest and fees

   969,078    $96,908      
  

 

 

       

Shares outstanding, June 30,

   62,316,502       59,251,836    

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

leases.

 

STOCK INCENTIVE COMPENSATION PLANSIncome Taxes

WARRANTS:

During the six months ended June 30, 2013, we issued to note holders and consultants warrants to purchase an aggregate of 3.7 million shares of our common stock. The warrants were immediately exercisable at prices ranging from $0.15 to $0.25 and had terms of from two to three years. We recognized approximately $109,000 and $165,000, respectively, of compensation costs related to warrants during the three and six months ended June 30, 2013. Total unrecognized compensation costs related to warrants as of June 30, 2013 was approximately $1,000 which is expected to be recognized over a weighted-average period of six months. The total fair value of warrants vested during the three and six months ended June 30, 2013 was approximately $108,000 and $167,000.

A summary of our warrant activity for the three and six months ended June 30, 2013 and 2012 follows:

Warrants

  Shares  Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Term

Outstanding at January 1, 2013

   35,957,583   $0.33    4.26 years

Granted

   1,700,000   $0.25    

Forfeited or expired

   (325,000 $0.37    
  

 

 

    

Outstanding at March 31, 2013

   37,332,583   $0.33    4.00 years
  

 

 

    

Granted

   2,010,000   $0.20    

Cancelled

   (2,000,000 $0.20    
  

 

 

    

Outstanding at June 30, 2013

   37,342,583   $0.33    3.75 years
  

 

 

    

Exercisable at June 30, 2013

   37,308,583   $0.33    3.75 years

Outstanding at January 1, 2012

   41,057,583   $0.35    4.86 years

Granted

   25,000   $0.25    

Forfeited or expired

   (100,000 $0.53    
  

 

 

    

Outstanding at March 31, 2012

   40,982,583   $0.35    4.61 years
  

 

 

    

Forfeited or expired

   (2,300,000 $0.32    
  

 

 

    

Outstanding at June 30, 2012

   38,682,583   $0.35    4.58 years
  

 

 

    

Exercisable at June 30, 2012

   37,615,583   $0.33    4.62 years

OPTIONS:

As of June 30, 2013, there were a total of 44,518,000 options available for grant and 6,443,000 options outstanding, 6,116,334 of which were exercisable, under our employee stock option plans.

As of June 30, 2013, there were 801,668 shares available for option grants and 100,000 options outstanding under the non-qualified directors’ plan, 80,000 of which were exercisable.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

A summary of our option activity for the three and six months ended June 30, 2013 and 2012 follows:

Options

  Shares  Weighted-
Average
Exercise
Price
   Weighted-Average
Remaining
Contractual  Term

Outstanding at January 1, 2013

   6,618,000   $0.32    8.29 years

Forfeited or expired

   (190,000 $0.79    
  

 

 

    

Outstanding at March 31, 2013

   6,428,000   $0.31    8.15 years
  

 

 

    

Granted

   300,000   $0.25    

Forfeited or expired

   (185,000 $0.38    
  

 

 

    

Outstanding at June 30, 2013

   6,543,000   $0.31    7.86 years
  

 

 

    

Exercisable at June 30, 2013

   6,196,334   $0.31    7.86 years
     

Outstanding at January 1, 2012

   8,795,400   $0.33    7.74 years

Forfeited or expired

   (40,000 $0.38    
  

 

 

    

Outstanding at March 31, 2012

   8,755,400   $0.33    7.49 years
  

 

 

    

Forfeited or expired

   (119,500 $0.35    
  

 

 

    

Outstanding at June 30, 2012

   8,635,900   $0.33    7.24 years
  

 

 

    

Exercisable at June 30, 2012

   7,978,000   $0.33    7.15 years

Total recognized compensation costs during the three and six months ended June 30, 2013 were approximately $8,000 and $23,000, respectively. As of June 30, 2013, there was approximately $35,000 of unrecognized compensation cost related to options expected to be recognized over a weighted-average period of 10 months. We might have recognized approximately $5,000 and $8,000, respectively, of tax benefits attributable to stock-based compensation expense recorded during the three and six months ended June 30, 2013. However, this potential benefit was fully offset by our valuation allowance due to the aforementioned significant uncertainty of future realization. The total fair value of options vested during the three and six months ended June 30, 2013 was approximately $20,000 and $30,000, respectively.

The following table lists the assumptions utilized in applying the Black-Scholes valuation model for options and warrants.

   Six months ended June 30, 
   2013 2012 

Expected volatility

  160%  160

Expected life (in years) of options

  3    

Expected life (in years) of warrants

  2-3  3  

Risk-free interest rate range, options

  0.66%    

Risk-free interest rate range, warrants

  0.23-0.74%  0.57

Expected dividend yield

  0%  0

*None were granted during the period.

NOTE 8 – INCOMETAXES

- We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. OurHowever, our provisions for income taxes for the three2020 and six months ended June 30, 2013 and 2012, consist solely of certain2019 include only state taxes.

At June 30, 2013, we have federal net operating loss carryforwards of approximately $35.5 million, the deductibility of $29.1 million of which is available but subject to limitations under Section 382 of the Internal Revenue Code. Approximately $361,000 of any net operating losses prior to the January 2009 ownership change (“the earlier change”) can be used to offset taxable income annually. In addition, we can offset our taxable income each year by approximately $274,000 of the net operating losses which incurred between the earlier change and the August 2011 ownership change. We estimate that 59.6% of the $29.1 million pre-change losses will expire and be unavailable to offset our future taxable income.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

taxes. 

 

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e.(i.e., tax years 20092017 and thereafter federally, and earlier for certain other jurisdictions)federally), and has concluded that there arehave been no uncertain tax positions as(as defined in generally accepted accounting principles,GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Concentration of Credit Risk - The Company maintains its cash and cash equivalents with a financial institution which management believes to be of high credit quality. Their accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 in coverage. The Company had an uninsured cash balance of $595,340 as of September 30, 2020 and no uninsured cash balances as of December 31, 2019.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

3. CURRENT ASSETS

NOTE 9 – PERSHAREDATA

ForCash and Restricted Cash - On April 23, 2020, the periods presented,Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the Paycheck Protection Program “PPP”. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in it’s PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

Cash and restricted cash consists of the following table sets forthat September 30, 2020 and December 31, 2019:

  September 30, 2020 December 31, 2019
     
Cash $35,566  $69,327 
Restricted Cash  845,340    
         
Total cash and restricted cash shown in the        
 consolidated statement of cash flows $880,906  $69,327 

Other current assets consists of the computationfollowing at September 30, 2020 and December 31, 2019:

  September 30, 2020 December 31, 2019
     
Due from escrow account $477  $152,263 
Loans to others  33,849   42,676 
Security and lease deposits  3,500   3,500 
Capitalized portion of lease  952   1,808 
Prepaid expenses  142,946   452,953 
Miscellaneous receivable  334,514   325,660 
         
Other current asset $516,238  $978,860 

4. PROPERTY AND EQUIPMENT

Property and equipment, net, consists of basicthe following at September 30, 2020 and diluted (loss) earningsDecember 31, 2019:

  September 30, 2020 December 31, 2019
     
Property and equipment $6,616  $1,549 
Less accumulated depreciation  (1,244)  (310)
Property and equipment - net $5,372  $1,239 

Depreciation expense for the nine-month periods ended September 30, 2020 and 2019 is $934 and $225, respectively. A laptop was acquired in January of 2020.

5. LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at September 30, 2020 and December 31, 2019:

  September 30, 2020 December 31, 2019
     
Leasehold improvements $2,992  $2,992 
Less accumulated amortization  (2,992)  (2,992)
Leasehold improvements - net $  $ 

Amortization expense for the nine-month periods ended September 30, 2020 and 2019 is $0 and $299, respectively.

6. RELATED PARTY LOANS PAYABLE

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of September 30, 2020 and December 31, 2019, there are the following related party notes payable:

  September 30, 2020 December 31, 2019
         
Related party loans payable $147,761  $342,670 

7. DEBT

As of September 30, 2020 and December 31, 2019, the balance was as follows:

  September 30, 2020 December 31, 2019
         
Notes payable $10,422,356  $12,352,189 

During the nine-month period ended September 30, 2020, there have been 12 additional convertible notes issued totaling $628,540. There have been 56 convertible notes totaling $3,802,213 converted to stock.

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the PPP. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

  September 30, 2020 December 31, 2019
     
Advanzeon parent $3,437,343  $5,010,016 
PVMS  6,985,013   7,342,173 
  $10,422,356  $12,352,189 

At Advanzeon, the total notes issued year-to-date and their dollar values were as follows:

  September 30, 2020 December 31, 2019
     
Number of notes issued  3    
         
Dollar value $221,540  $ 

All debts issued during the nine-month period ended September 30, 2020 are short-term in nature and have a stated interest rate of 10%.

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

  September 30, 2020 December 31, 2019
     
Number of notes issued  9   51 
         
Dollar value $407,000  $2,289,250 

All debt is short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12%.

8. CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

1.A lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. The case has been dormant over a year. The Court has not dismissed it for lack of prosecution yet. The Court does this on its own motion and because of COVID, it is not doing this at this time.
2.Interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit referenced in (1).
3.Advanzeon won a decision on a court case against Universal Healthcare. The attorney’s fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

As of September 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:

  September 30, 2020 December 31, 2019
     
Disputed note payable $450,000  $450,000 
Disputed interest payable  171,247   171,247 
Pending attorney fees  21,412   21,412 
         
Total contingent liability $642,659  $642,659 

9. OTHER ACCRUED LIABILITIES

As of September 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows:

  September 30, 2020 December 31, 2019
     
Management compensation $8,973,353  $8,873,802 
Accrued interest non-related party  5,032,646   5,956,368 
Board of Director fees  37,500   1,050,000 
State fees     2,800 
Payroll liabilities  14,771    
Other accrued liabilities  35,222   8,817 
Total other accrued debt $14,093,492  $15,891,787 

10. RIGHT OF USE ASSETS

The Company entered into two leases, one for office space and one for an automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases. 

As of September 30, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
 under lease agreements
 $368,870 
     
Amortization of right of use assets  (85,992)
     
Total right of use assets as of September 30, 2020 $282,878 

Total amortization expense related to the right of use assets under the lease agreements was $54,660 and $62,135 for the nine-month periods ended September 30, 2020 and 2019, respectively.

11. RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space prior to the quarter ended September 30, 2020 that are classified as right of use assets and lease liabilities.

As of September 30, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments $368,870 
     
Principal payments made as of the nine month period ended September 30, 2020  (85,992)
     
Total right of use lease liabilities as of September 30, 2020 $282,878 

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of September 30, 2020:

Total future minimum lease payments $299,967 
     
Less present value discount  17,089 
     
Total right of use lease liabilities as of September 30, 2020  282,878 
     
Less current portion due within one year  137,992 
     
Long-term right of use liabilities $144,886 

Total maturities of lease liabilities as of September 30, 2020 are as follows:

  Total future    
  minimum lease Present value Right of use
  payments discount lease liabilities
2021  $150,041  $12,049  $137,992 
2022   121,926   4,534   117,392 
2023   28,000   506   27,494 
   $299,967  $17,089  $282,878 

12. COMMON STOCK

During the nine-month period ended September 30, 2020, the Company issued 45,855,182 shares of its common stock as follows:

On April 01, 2020, the Company issued 3,262,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $652,500. The stock was issued at $0.20 per share.

On April 01, 2020, the Company issued 1,087,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $217,500. The stock was issued at $0.20 per share.

On April 01, 2020, the Company issued 1,087,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $217,500. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 14,584,350 shares of its common stock to existing note holders who elected to convert promissory notes plus accrued and unpaid interest totaling $2,916,869. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 1,327,252 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $265,450. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 2,156,515 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $431,303. The stock was issued at $0.20 per share.

On May 15, 2020, the Company issued 1,263,745 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $139,012. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 4,284,565 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $471,302. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 7,210,168 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $793,118. The stock was issued at $0.11 per share.

On May 18, 2020, the Company issued 700,751 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $77,083. The stock was issued at $0.11 per share.

On May 21, 2020, the Company issued 502,434 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,268. The stock was issued at $0.11 per share. 

On May 25, 2020, the Company issued 319,627 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $35,159. The stock was issued at $0.11 per share.

On May 25, 2020, the Company issued 333,824 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $36,721. The stock was issued at $0.11 per share.

On May 26, 2020, the Company issued 781,206 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $85,933. The stock was issued at $0.11 per share.

On May 28, 2020, the Company issued 884,555 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $97,301. The stock was issued at $0.11 per share.

On May 29, 2020, the Company issued 937,116 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $103,083. The stock was issued at $0.11 per share.

On June 1, 2020, the Company issued 1,024,189 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $112,661. The stocks was issued at $0.11 per share.

On June 05, 2020, the Company issued 668,797 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $73,568. The stock was issued at $0.11 per share.

On June 05, 2020, the Company issued 603,987 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $66,439. The stock was issued at $0.11 per share.

On June 12, 2020, the Company issued 1,564,245 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $172,067. The stock was issued at $0.11 per share.

On June 18, 2020, the Company issued 504,957 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,545. The stock was issued at $0.11 per share.

On July 02, 2020, the Company issued 765,399 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $84,194. The stock was issued at $0.11 per share.

During the nine-month period ended September 30, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share attributable to common stockholders (dollars in thousands, except per share data):on the total value of $16,000.

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
   2013  2012   2013  2012 

Numerator:

      

Net (loss) income attributable to common stockholders

  $(1,647 $1,607    $(3,054 $1,687  

Add impact of assumed conversions:

      

Interest on convertible debts

   —      231     —      223  
  

 

 

  

 

 

   

 

 

  

 

 

 

Net income (loss) attributable to common stockholders after assumed conversions

   (1,647 $1,838     (3,054 $1,910  

Denominator:

      

Weighted average common shares – basic

   61,102    59,252     60,427    59,252  
  

 

 

    

 

 

  

Effect of dilutive securities:

   n/a      n/a   

Series C convertible preferred stock

    3,300      3,300  

Series D convertible preferred stock

    5,182      6,551  

Stock options

    —        —    

Warrants

    —        —    

Convertible debts

    20,700      12,684  
   

 

 

    

 

 

 

Weighted average common shares – diluted

    88,434      81,787  
   

 

 

    

 

 

 

(Loss) earnings per share:

      

Basic

  $(0.03 $0.03    $(0.05 $0.03  
  

 

 

  

 

 

   

 

 

  

 

 

 

Diluted

   n/a   $0.02     n/a   $0.02  
   

 

 

    

 

 

 

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the Company’s common stock for $15,000.

The warrants were issued during May of 2017 for $0.03 per share.

NOTE 10 – SUBSEQUENT EVENTS13. LEGAL PROCEEDINGS

Other than

The Company previously reported that the changeslitigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation. A final judgment in favor of the Plaintiff was entered on 02/01/2021 in the amount of $130,355.39. On 03/03/2021 the Company filed a Notice of Appeal of the judgment with the Second District Court of Appeal. The appeal is pending.

Except as disclosed above and in Part II Item 1, all of the legal proceedings for the nine-month period ended September 30, 2020, are disclosed in our outstanding debt instruments described in Note 3, noannual report on Form10-K filed on April 9, 2020. 

14. SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events were identified that in our opinion require accounting recognition or disclosure inthrough November 9, 2020, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $60,000 of convertible-promissory notes. All of the debt matures in 2021 and has a stated interest rate of 12% and is unsecured. Concurrent with the exceptionissuance of debt, the following:

Warrant issuance

During July 2013, weCompany has issued 50,000 warrants to purchase 2.3 million common shares to three individuals in lieu of cash compensation for marketing services. The warrants expire in July 2016 and can be exercised at aan average exercise price of $0.25 per share. Of$0.04. At the 2.3 million total issued, 2.1 million were immediately vested attime of issuance, with the remaining vesting over the next 24 months.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

all warrants had a three or five year term.

 

ITEM 2.MANAGEMENTS DISCUSSIONAND ANALYSISOF FINANCIAL CONDITIONAND RESULTSOF OPERATIONS

In addition to historical information, theITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information contains forward-looking statements as defined under federal securities laws for Comprehensive Care Corporation (referred to herein as the “Company,” or “CompCare”) and its subsidiaries (collectively referred to herein as “we,” “us” or “our”). In our case, such statements include, but are not limited to, the overall performance of the healthcare market, our anticipated operating results, the success of our Pharmacy Savings Management Program, financial resources, increases in revenues, increased profitability, interest expense, growth and expansion, anticipated favorable results from legal actions, the ability to obtain new and maintain existing behavioral healthcare contracts and the profitability, if any, of such behavioral healthcare contracts. These statements are based on current expectations, estimates and projections about the industry and markets in which we operate, the customers we serve and management’s beliefs and assumptions. Forward-looking statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability of our capitated contracts, cost of care, seasonality, our ability to obtain additional financing, and other risks detailed herein and from time to time in our filings with the SEC. The following discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes thereto and in conjunction with Managements’ Discussion and Analysis of CompCareFinancial Condition and subsidiaries appearing elsewhereResults of Operations in this report.our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

OVERVIEW

We provide managed careThis report includes forward-looking statements, the realization of which may be affected by certain important factors discussed previously above under Item 1A, “Risk Factors.”

Overview

The Company through its wholly owned subsidiary Pharmacy Value Management Solutions, Inc. administers and operates a medically driven sleep apnea program branded SleepMaster Solutions™ (“SMS”). Management believes that SMS is the largest provider of these combined services in the behavioralnation. We are in all 50 states and provide a turnkey solution designed to effectively keep drivers on the road with no down time, compliant with DOT regulations, improve their health, substance abuse, and pharmacysignificantly decrease legal liability risk for the employer. We are vertically integrated, and we provide a “Program” of services that addresses all the needs of a corporate transportation system, union or other driver-related organizations. We believe we are the only company capable of providing the full range of needed services in a timely manner.

Our services start with the identification of the target population and the potential risk the client currently has. We can do this through our SMS Program, which includes the ability to screen every driver to identify if signs and symptoms of sleep apnea are present. We can then take this data and provide the employer with a list of those drivers that should be tested and the statistical likelihood of the percentage of those drivers who will test positive for obstructive sleep apnea (OSA). Together with the employer/union, SMS provides a realistic time frame, actual total cost, and process for testing all drivers who need to be tested. For those drivers testing positive for OSA, we then provide the appropriate treatment such that the driver will meet the DOT requirements and remain on the road. We monitor 365 days per year driver’s usage of the treatment device according to DOT standards and we report that usage to all stakeholders as required/permitted. We utilize mathematical algorithms to determine if the driver is predicatively meeting the annual DOT requirements for usage. Using those predictive algorithms, we reach out to those drivers and provide case management, fields, primarilyencouragement designed to solve problems such that the driver increases usage, if necessary, and remains compliant.

SMS constructed its model based upon the foregoing principles. The SMS Program includes all processes attended in sleep apnea screening, testing, treatment, monitoring and overall management of commercial Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans,drivers’ as well as self-insured companies, unions,their employers’ needs. We have successfully established relationships with national health care clinic providers, all with certified medical examiner (“CME”) status. These clinics total almost 1,000 throughout the U.S. We also have both formal and Taft-Hartley healthinformal relationships with employers; municipalities; a significant veteran’s group; union and welfare funds.non-union driving organizations; suppliers of home sleep testing equipment and a variety of OSA treatment devices; and, a national network of telemedicine sleep specialists covering all 50 states. We have an internal medical team for governance and protocol purposes and a customer service department that interfaces directly with our drivers. We also have a marketing team that regularly interfaces with our existing accounts and markets our services to potential new accounts. Our managed care operations include administrative service agreements, fee-for-service agreements,services are performed utilizing a best medical practices model and capitation contracts.

SOURCES OF REVENUE

Our revenue can be segregated intoan efficient, cost-effective delivery system. We obtain the following significant categories (amounts in thousands):required equipment on a per order basis from a durable medical equipment distributor.

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2013   2012   2013   2012 

At-risk behavioral contracts

  $922    $7,490    $1,836    $14,966  

Administrative services only contracts

   156     853     459     1,670  

At-risk pharmacy contracts

   —       9,781     —       19,378  
  

 

 

   

 

 

   

 

 

   

 

 

 
  $1,078    $18,124    $2,295    $36,014  
  

 

 

   

 

 

   

 

 

   

 

 

 

Our customer base primarily includes regional health plans that do not have their own behavioral network. We provide services primarily through a network of contracted providers that includes:Revenue is recognized when billed, which is approximately when the testing service is performed, or CPAP machine is shipped.

 

psychiatrists;During the three-month period ending September 30, 2020, the majority of our revenue continued to be received from patient referrals from only certain of the clinics operated by Concentra Health Services. During this period and as a result of the Coronavirus pandemic, the Federal Motor Carrier Safety Administration (“FMCSA”), which had previously suspended the requirement that interstate commercial drivers have a prescribed DOT medical exam from a certified medical examiner, extended the medical exam suspension from September 30, 2020 until the end of the year. This action by the FMCSA, coupled with the effect of the pandemic, caused a significant number of clinics that we rely upon for referrals to either continue to be closed, close anew or operate with reduced staffing and reduced capacity. All of the foregoing resulted in fewer patients. Additionally, many commercial drivers, who, but for the aforesaid medical exam suspension, would have gone to the Concentra clinics for their required medical exam, continue to elect to wait until the suspension expires. All of those events materially reduced our referral resources. We did continue to receive revenue from certain Concentra referrals, other clinic referrals and some of our in-house accounts, such as PG&E, the Veteran’s organization with whom we contract, and others, but this patient flow was materially reduced, as well. However, we expect to see increased revenue from these accounts in the fourth quarter.

 

psychologists;

therapists;

other licensed healthcare professionals;

psychiatric hospitals;

general medical facilitiesDuring this period, we added a companion product to our CPAP treatment program, a branded sanitizer device. We also have beta tested our WatchPat One device. The WatchPat One device shortens the turnaround time for our home sleep test results by as much as five days. As we anticipate a large surge of drivers going forward, we believe this shortened turnaround time will be a significant, positive decision for our current clients and our new clients to use our services. During the period we continued with psychiatric beds;

residential treatment centers;our beta testing program with Sleep Cycle. The results have been very positive and

other treatment facilities.

The services provided through our provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient programs and crisis intervention services. We do not directly provide treatment or own any treatment facility.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

we anticipate a full-fledged joint marketing launch to Sleep Cycle customers by mid-year 2021.

 

We typically enter into contracts on an annual basiscontinued our effort to provide managed behavioral healthcare, substance abuse, and pharmacy management services toincrease our customers’ members. Our arrangementspresence with our clients fall into two broad categories:

At-risk arrangements under which our clients pay us a fixed fee per member in exchange for our assumption of the financial risk of providing services; and

ASO arrangements where we manage behavioral healthcare programs or perform various managed care services, such as clinical care management, provider network development, and claims processing without assuming financial risk for member behavioral healthcare costs.

unions. We also cover pharmacy management services, where we receive an additional per-member per-month amount. We manage pharmacy services through the collection and analysis of pharmacy claims data which is provided by the health plan’s pharmacy benefit manager (“PBM”), whose primary functions are claims adjudication and drug cost negotiation. Through data analysis and usage evaluation against clinically sound, evidence-based criteria, we are able to identify ineffective, inappropriate and costly drug utilization. Our approach is to address these issues in a collaborative manner with the primary care physicians and psychiatrists through the provision of useful information based on our analysis. Our goal is to produce positive outcomes for patients while controlling pharmacy costs.

Under at-risk arrangements, the number of covered members as reported to us by our clients determines the amount of premiums we receive, which is independent of the cost of services rendered to members. The amount of premiums we receive for each member is fixed by our contract at the beginning of our contract term. Under certain circumstances these premiums may be subsequently adjusted up or down, or the contract terminated, generally at the commencement of each renewal period.

Our largest costs are those of behavioral health services and pharmacy drugs that we provide, which is based primarily on our arrangements with healthcare providers. Since we are subject to increases in healthcare operating costs based on an increase in the number and frequency of our members seeking behavioral care services, our profitability depends on our ability to predict and effectively manage these costs in relation to the fixed premiums we receive under at-risk arrangements. Providing services on an at-risk basis exposes us to the risk that our contracts may ultimately be unprofitable if we are unable to control or otherwise anticipate healthcare costs. Accrued claims payable and claims expense are our most significant critical accounting estimates. See “Critical Accounting Policies and Estimates” below.

We manage programs through which services are provided to recipients in five states. Our objective is to provide easily accessible, high quality behavioral healthcare and pharmacy services and to manage costs through measures such as the monitoring of hospital inpatient admissions and the review of authorizations for various types of outpatient therapy. Our goal is to combine access to quality behavioral healthcare services with effective management controls in order to ensure the most cost-effective use of healthcare resources.

Our programs and services include:

management of prescription drugs on an at-risk basis for health plans;

fully integrated behavioral healthcare and pharmacy management services;

analytic services for medical and pharmacy claims for medical integration of behavioral and medical care coordination;

case management/utilization review services;

administrative services management;

preferred provider network development;

management and physician advisor reviews; and

overall care management services.

We continue our efforts to expand our new Pharmacy Savings Management Program, marketed through our dedicated, wholly-owned subsidiary CompCare Pharmacy Solutions, Inc. For health plans, self insured entities, unions, and Taft-Hartley health and welfare funds, we will offer to manage on an at-risk basis prescription drug programs. Through the use of selected pharmacy benefits managers, pharmacy data analytics, and the development of cost-saving ancillary pharmacy programs, we believe we can materially reduce drug costs for our clients that utilize our program. Our marketing efforts of this program are receiving positive traction.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

RECENT DEVELOPMENTS

Pharmacy Savings Management Program; New Business

In March of 2013, wesuccessfully entered into an agreement with Local No. 29a large group of Teamsters, whose healthcare benefits are substantially paid for by the Laborers International Union of North America to provide our Pharmacy Savings Management Program, and in May 2013, we signedgroup. We also established a Pharmacy Savings Management agreement with Utica City (NY) School District. Both programs are scheduled to launch in January of 2014.

Contract Terminations

On July 31, 2013, our contract to provide ASO services to a health plan serving approximately 49,000 Medicare and Healthy Families program members expired without renewal. The contract accounted for 12.5%, or $0.3 million of our revenues for the six months ended June 30, 2013. The health plan had been a client since January of 2011.

Our at-risk contractrelationship with a health plan serving approximately 37,000 CHIP members is expected to expire without renewal during the third or fourth quarter of 2013 at a point yet to be chosen by the health plan. The contract accountedlarge third-party payer for 20.9%, or $0.5 million of our revenues for the six months ended June 30, 2013. The health plan has been a client since April of 2000.

Retirement of President and Appointment of Pharmacy Savings Management Program President

On April 22, 2013, we were notified by our President, Robert R. Kulbick, that he needed to retire for medical reasons effective May 1, 2013. We have named Ramon Martinez to direct our Pharmacy Savings Management Program as President of CompCare Pharmacy Solutions, Inc., our wholly-owned subsidiary dedicated to marketing our pharmacy savings program. Mr. Martinez was working with the Company on its new, innovative pharmacy savings program as a Senior Management Advisor since August 2012.

Debt Matters

SeeLIQUIDITYAND CAPITAL RESOURCES, below.

RESULTSOF OPERATIONS

Three months ended June 30, 2013vs. 2012

With the expiration of our at-risk behavioral health and pharmacy contracts in Puerto Rico on December 31, 2012, which then comprised approximately 83% of the Company’s total revenue, our operating revenues have decreased significantly. Prior to December 31, 2012, anticipating this decrease, we accelerated our efforts to advance the Company’s Pharmacy Savings Management Program so that we would be prepared to commence aggressively marketing it by January 1, 2013, which we did in early January. Simultaneously, we significantly reduced salaries, decreased our work force and generally cut back expenses. To date, we have entered into two pharmacy savings management agreements, both scheduled for launch in January 2014. We are actively engaged in discussions with a number of other potential pharmacyunion trust funds and labor unions. Their main account customers.is a large national delivery service. We expect to see revenue from this relationship in the fourth quarter. As clinics reopen we expect to see increased revenue from this source and from our new and existing accounts in the fourth quarter. Other relationships that we have established are not expected to come online until the first part of 2021.

Sources of Revenue

Three-month periods ended September 30, 2020 and 2019

A quantitative summary of our revenues by source category for the three-month periods ended September 30, 2020 and 2019:

  2020 2019 Change
              
OSA- related  $127,070  $68,173  $58,897 

Results of Operations

OSA services increased to $127,070 in 2020 from $68,173 in 2019. The Company’s shift of focus away fromincrease was primarily the behavioral health/Medicare/Medicaid segmentsresult of the healthcare market to pharmacy savings market was occasioned by reason of the Company’s management’s belief that significantly greater margins, less regulation and ease of closing transactions exists in the pharmacy management sector of healthcare. The Company believes that its focusConcentra account. Last year, on its Pharmacy Savings Management Program, coupledMay 14, 2019, we reached an agreement with its decreased operating expenses, will giveConcentra whereby Concentra engaged the Company, and the best opportunityCompany accepted the engagement, to achieve profitability during 2014.

Revenues:

At-risk behavioral health contracts: Operating revenues from at-risk contracts decreased by 87.7%, or approximately $6.6 million, to $0.9 million for the three months ended June 30, 2013, compared to $7.5 million for the three months ended June 30, 2012. As noted above, the decreaseserve as one of Concentra’s preferred national sleep apnea services provider. The launch was primarily attributable to the expiration of our Puerto Rico contractinitiated during the fourth quarter of 2012 that accounted for $4.4 million2019.

Cost of revenuerevenues increased to $69,599 in 2020 from $2,394 in 2019. In 2019, the Company received a credit of $34,417 as a settlement.

General and administrative expense

General and administrative expense in total for the three monthsmonth periods ended JuneSeptember 30, 2012,2020 and 2019 was as follows:

2020  $620,126 
2019   428,077 
Change  $192,049 
Percentage Change   44.86%

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the expirationcost of contracts in Louisiana and Michigan that generatedbeing a totalpublic entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of $2.1 million in revenue during the quarter ended June 30, 2012.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

ASO contracts: Revenue from ASO contracts decreased by 81.7%, or approximately $0.7 million, to $0.2 millionthese expenses for the three monthsmonth periods ended JuneSeptember 30, 20132020 and 2019 is as follows:

  2020 2019 Change Percent Change
         
Parent (Debtor-In-Possession)  $359,887  $118,096  $241,791   204.74%
PVMS   260,239   309,981   (49,742)  (16.05)%
                  
Total  $620,126  $428,077  $192,049   44.86%

Parent Company Level (Debtor-In-Possession)

  2020 2019 Change Percent   Change
         
Professional fees $266,090  $34,329  $231,761   675.12%
Travel expense           %
Board of Directors fees     37,500   (37,500)  (100)%
Office supplies  52   16   36   225%
Rent expense     25,255   (25,255)  (100)%
Other  93,745   20,996   72,749   346.49%
                 
Total G & A $359,887  $118,096  $241,791   204.74%

Explanations of variations by line item follow:

Professional fees increased by $231,761. There is an increase in consulting service expenses of $118,250 due primarilyto new consulting service expense in the three-month period ended September 30, 2020 compared to the lossthree-month period ended September 30, 2019. Legal fees increased by $77,647 in order to continue with various lawsuits and with the bankruptcy proceeding. Accounting Fees increased by $22,869 due to services for special projects, some of which are related to the bankruptcy proceeding. Audit fees and filings increased by approximately $4,000 due to an amended filing of it’s 10K.

Travel expense stayed relatively the same.

Board of Directors fees decreased by $37,500. As of July 1, 2020, the Company has stopped paying Board of Director fees.

Rent expense decreased by 25,255 due to office lease moving to subsidiary level as of January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $72,749. This increase is mainly due to an increase in payroll related expenses of $99,551. The Company accrued CEO wages in the amount of $66,095 during the three-month period ended September 30, 2020 and the second quarter’s accrued CEO wages of $33,456 was moved from subsidiary level to parent level. The same will show as an decrease on the subsidiary level. TCA commissions decreased $24,013 due to moving the expense to subsidiary level. The same will show as an increase on the subsidiary level.

PVMS Subsidiary Level

  2020 2019 Change Percent Change
         
Payroll related $127,167  $129,457  $(2,290)  (1.77)%
Travel and related expense  5,834   60,048   (54,214)  (90.28)%
Professional fees  24,745   53,454   (28,709)  (53.71)%
Marketing costs  25,685   16,511   9,174   55.56%
Dues and subscriptions  211   200   11   5.50%
Office supplies  1,627   13,191   (11,564)  (87.67)%
Rent expense  30,115   12,941   17,174   132.71%
Other  44,855   24,179   20,676   85.51%
                 
Total G & A $260,239  $309,981  $(49,742)  (16.05)%

Explanations of variations by line item follow:

Payroll related expenses decreased by $2,290. The second quarter accrued CEO wages of $33,456 was moved to the parent level. The same will show as an increase on the parent level. The company had 4 employees in the three-month period ended September 30, 2020 that were not included in the comparable period in 2019.

Travel expense decreased by $54,214 due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional fees decreased by $28,709. The decrease is mainly due to the Company no longer using 2 consultants in the three-month period ended September 30, 2020 that were used in the comparable period in 2019.

Marketing costs increased by $9,174. In July 2020, the company hired a customernew marketing firm.

Office supplies decreased by $11,564 due to office supplies were fully stocked going into the new year of 2020.

Rent expense increased by $17,174 due to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a decrease on the parent level.

Other general and administrative expense increased by $20,676. TCA commissions increased $23,488 due to moving the expense to subsidiary level. The same will show as an decrease on the parent level. Payroll tax expenses increased by $4,776 due to an increase in wages. There is a decrease in automobile expenses of $3,154 due to the COVID-19 pandemic. Other miscellaneous items decreased by $5,000.

Interest expense

Interest expense in total for the three-month periods ended September 30, 2020 and 2019 was as follows:

2020  $291,258 
2019   383,798 
Change  $(92,540)
Percentage Change   (24.11)%

A breakdown of the interest expense for the three-month periods ended September 30, 2020 and 2019 is as follows:

  2020 2019 Change
       
Parent (Debtor-In-Possession)  $108,570  $172,720  $(64,150)
PVMS   182,688   211,078   (28,390)
              
Total  $291,258  $383,798  $(92,540)

Sources of Revenue

Nine-month periods ended September 30, 2020 and 2019

A quantitative summary of our revenues by source category for the nine-month periods ended September 30, 2020 and 2019:

  2020 2019 Change
              
OSA- related  $358,062  $226,549  $131,513 

Results of Operations

OSA services increased to $358,062 in 2020 from $226,549 in 2019. The increase was primarily the result of the Concentra account. Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as one of Concentra’s preferred national sleep apnea services provider. The launch was initiated during the fourth quarter of 2012 that had accounted2019.

Cost of revenues increased to $199,508 in 2020 from $110,211 in 2019 due to an increase in sales.

General and administrative expense

General and administrative expense in total for approximately $0.4 millionthe nine-month periods ended September 30, 2020 and 2019 was as follows:

2020  $1,931,591 
2019   1,269,920 
Change  $661,671 
Percentage Change   52.10%

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of business during the quarter ended June 30, 2012.

Pharmacy management contracts: Duebeing a public entity. Expenses at PVMS are solely related to the expirationOSA services segment. A breakdown of our major contractthese expenses as September 30, 2020 and 2019 is as follows:

  2020 2019 Change Percent Change
         
Parent (Debtor-In-Possession)  $899,145  $470,917  $428,228   90.94%
PVMS   1,032,446   799,003   233,443   29.22%
                  
Total  $1,931,591  $1,269,920  $661,671   52.10%

Parent Company Level (Debtor-In-Possession)

        Percent
  2020 2019 Change Change
         
Professional fees $675,959  $245,594  $430,365   175.23%
Travel expense  67   3,815   (3,748)  (98.24)%
Board of Directors fees  95,000   112,500   (17,500)  (15.56)%
Office supplies  547   336   211   62.80%
Rent expense     76,532   (76,532)  (100)%
Other  127,572   32,140   95,432   296.93%
                 
Total general and administrative $899,145  $470,917  $428,228   90.94%

Explanations of variations by line item follow:

Professional fees increased $430,365. The increase is mainly due to new consulting service expenses of $354,750 in Puerto Rico, we did not generate any revenue for the three monthsnine-month period ended JuneSeptember 30, 2013, as compared to $9.8 million for the same period in 2012.

Costs of revenues: Anticipating our decrease in revenue commencing January 1, 2013, we successfully decreased our costs by 95.1%, or approximately $13.0 million, for the three months ended June 30, 2013 as2020 compared to the three monthsnine-month period ended JuneSeptember 30, 2012 for reasons set forth2019. Legal fees increased by $132,671 in order to continue with various lawsuits and with the following three paragraphs.

Behavioral health contracts: Claims expense on at-risk contractsbankruptcy proceeding. Audit fees decreased approximately $6.0 million due to expense reductions and cost containment measures mentioned above and a reduction to claims expense of approximately $0.3 million relating to favorable claims experience from our former major Puerto Rico contract.

Pharmacy drug costs: Pharmacy costs decreased 100%, or approximately $6.2 million,by $53,467 due to the expiration of our Puerto Rico pharmacy contract on December 31, 2012.

fact that the 2015 - 2017 10-K was filed in January 2019. Other healthcare operating costs: Other healthcare costs, attributable to servicing both at-risk contracts and ASO contracts, decreased approximately $1.2 million from approximately $1.8 million for the three months ended June 30, 2012 to approximately $0.6 million for the three months ended June 30, 2013 due primarily to reductions in salaries and benefits attributable to workforce reductions.

General and administrative expense: General and administrative expensesprofessional fees decreased by 33.2%, or approximately $0.7 million, to $1.5 million for the three months ended June 30, 2013 as compared to $2.2 million for the three months ended June 30, 2012, primarily consisting of a $0.3 million decrease in salaries and benefits$4,000.

Travel expense decreased $3,748 due to workforce reductions, a $0.2 million reductionthe COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in miscellaneousperson visits.

Board of Directors fees reduceddecreased $17,500. As of July 1, 2020, The Company has stopped paying Board of Director fees.

Rent expense decreased $76,532 due to rent expense moving from parent level to subsidiary level as of $0.1 million due to lease renegotiation, and a $0.1 million reduction in consulting fees due to less usage. As a percentage of total operating revenue,January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $95,432. D&O Insurance expense increased by $25,324 due to 137.9%a new D&O insurance that started in June 2019. Payroll related expenses increased by $99,551. The Company accrued CEO wages in the amount of $66,095 during the three-month period ended September 30, 2020 and the second quarter accrued CEO wages of $33,456 were moved from subsidiary level to the parent level. The same will show as an decrease on the subsidiary level. TCA commissions decreased $23,263 due to moving the expense to subsidiary level. The same will show as an increase on the subsidiary level. Taxes decreased by $6,137. Delaware taxes were properly accrued for 2019 and property taxes for 2018 was paid in 2019.

PVMS Subsidiary Level

        Percent
  2020 2019 Change Change
         
Payroll related $546,910  $341,769  $205,141   60.02%
Travel and related expense  81,059   151,372   (70,313)  (46.45)%
Professional fees  133,802   135,201   (1,399)  (1.03)%
Marketing costs  60,277   33,740   26,537   78.65%
Dues and subscriptions  419   841   (422)  (50.18)%
Office supplies  5,704   30,768   (25,064)  (81.46)%
Rent expense  96,048   35,942   60,106   167.23%
Other  108,227   69,370   38,857   56.01%
                 
Total general and administrative $1,032,446  $799,003  $233,443   29.22%

Explanations of variations by line item follow:

Payroll related expenses increased $205,141. The Company hired 4 employees during the threenine months ended JuneSeptember 30, 2013, compared to 12.3% for the three months ended June 30, 2012, due to significantly lower operating revenue.

Interest expense. Interest expense, excluding amortization of debt discount, increased by 26.5%, or approximately $0.1 million for the three months ended June 30, 2013, as compared to the three months ended June 30, 2012 due to an increase2020 that were not included in the effective interest rate on debt for the three months ended June 30, 2013, to approximately 21.4% from 16.7% for the samecomparable period in 2012, net of2019. The Company paid the effect of a small declineCEO $32,699 and accrued wages in the weighted average amount of debt outstanding to $9.2 million from $9.3 million for the three months ended June 30, 2013,vs. 2012 . The increase in the effective interest rate is attributable to the inclusion in interest expense of a pro-rata share of origination and other closing related fees from the six-month senior secured credit facility that began May 3, 2013.

Six months ended June 30, 2013vs. 2012

Revenues:

At-risk behavioral health contracts: Operating revenues from at-risk contracts decreased by 87.7%, or approximately $13.1 million, to $1.8 million for the six months ended June 30, 2013, compared to $15.0 million for the six months ended June 30, 2012. As noted above, the decrease was primarily attributable to the expiration of the Puerto Rico contract during the fourth quarter of 2012 that accounted for $8.7 million of revenue for the six months ended June 30, 2012, and the expiration of contracts in Louisiana and Michigan that generated a total of $4.2 million in revenue$33,456 during the six months ended June 30, 2012.

ASO contracts: Revenue2020. The second quarter accrued wages of $33,456 were moved from ASO contracts decreased by 72.5%, or approximately $1.2 million, to $0.5 million for the six months ended June 30, 2013 due primarilysubsidiary level to the loss of a customer duringparent level in September 2020. The same will show as an increase on the fourth quarter of 2012 that had accounted for $0.9 million of business during the same period ended June 30, 2012.

Pharmacy management contracts: Due to the expiration of our major contract in Puerto Rico, we did not generate any revenue for the six months ended June 30, 2013, as compared to $19.4 million for the same period in 2012.

Costs of revenues:Anticipating our decrease in revenue commencing January 1, 2013, we successfully decreased our costs by 95.2%, or approximately $28.9 million for the six months ended June 30, 2013, as compared to the six months ended June 30, 2012 for reasons set forth in the following three paragraphs.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

parent level.

 

Behavioral health contracts: ClaimsTravel expense on at-risk contracts decreased by 99.1%, or approximately $11.0 million, to $0.1 million for the six months ended June 30, 2013 as compared to the six months ended June 30, 2012 due to expense reductions and cost containment measures mentioned above and a reduction to claims expense of approximately $1.0 million relating to favorable claims experience from our former major Puerto Rico contract.

Pharmacy drug costs: Pharmacy costs decreased 100%, or approximately $15.9 million,$70,313 due to the expirationCOVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional Fees stayed relatively the same.

Marketing costs increased by $26,537. The Company hired an advertising firm in the 3rd quarter of our Puerto Rico pharmacy contract2019 to work on December 31, 2012.

Other healthcare operating costs: Other healthcare costs, attributable to servicing both at-risk contractsthe company’s website and ASO contracts, decreased approximately 63.9%, or $2.4 million, from approximately $3.8 million forother marketing responsibilities and is still with the six months endedCompany as of June 30, 2012 to approximately $1.4 million for the six months ended June 30, 2013.2020. In July 2020, The reduction is primarilyCompany hired a new marketing firm.

Office supplies decreased by $25,064 due to a $1.5 million decrease in salaries and benefitsoffice supplies were fully stocked going into the new year of 2020.

Rent expense increased $60,106 due to workforce reductions, a $0.4 million reduction in purchased services, and a $0.2 million decrease in medical director and case review fees.

General and administrative expense: General and administrative expenses decreased by 33.7%, or approximately $1.5 million (after excluding a $1.6 million adjustment of legal expense for the six months ended June 30, 2012), to $2.9 million for the six months ended June 30, 2013 as compared to $4.3 million for the six months ended June 30, 2012 due primarily to a $0.7 million decrease in salaries and benefits due to workforce reductions, a $0.2 million reduction in miscellaneous fees, and a $0.2 million reduction in rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a result of lease renegotiation. As a percentage of total operating revenue,decrease on the parent level.

Other general and administrative expense increased by $38,857 due to 125.4%a fraudulent charge of $9,500 and an increase in payroll taxes of $15,540 because of an increase in wages. TCA commissions increased $23,488 due to moving the expense to subsidiary level. The same will show as an decrease on the parent level. Automobile expenses decreased $6,233 due to the COVID-19 pandemic. Bad debt expense decreased $3,510 due to a decrease in bad debt in the nine-month period ended September 30, 2020 than in the comparable period in 2019.

Interest expense

Interest expense in total for the six monthsnine-month periods ended JuneSeptember 30, 2013, compared to 12.1%2020 and 2019 was as follows:

2020  $1,393,659 
2019   1,052,991 
Change  $340,668 
Percentage Change   32.35%

A breakdown of the interest expense for the six monthsnine-month periods ended JuneSeptember 30, 2012, due2020 and 2019 is as follows:

  2020 2019 Change
       
Parent (Debtor-In-Possession)  $745,022  $498,905  $246,117 
PVMS   648,637   554,086   94,551 
              
Total  $1,393,659  $1,052,991  $340,668 

Financial Condition

Liquidity and Capital Resources

During the nine-month period ended September 30, 2020, we funded our operations from revenues and $628,540 in private borrowings. As a result of the coronavirus pandemic some of our traditional sources of private borrowing have not been accessible. We have had to significantly lower operating revenue.

Interest expense: Interest expense, excluding amortization of debt discount, increased by 11.6%, or approximately $88,000, for the six months ended June 30, 2013, as comparedobtain private borrowing on terms less favorable than we were able to prior to the six months ended June 30, 2012 duepandemic. We will continue to an increasefund our operations from these sources until we are able to produce operating revenue sufficient to cover our cost structure. In the event we are not able to secure such funding, our operations will be adversely affected.

Short Term: We funded our operations with revenues from sales and private borrowings.

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the effective interest rate on debt forprincipal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the six months ended June 30, 2013, to approximately 18.3% from 16.2% forPaycheck Protection Program. On May 22, 2020, the same periodBank notified PVMS that the loan was in 2012. It is also affected by an increasedefault as a result of false statements made in the weighted average amount of debt outstandingloan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to $9.2 million for the six months ended June 30, 2013 from $9.3 million for the comparable prior period. The increase in the effective interest rate is attributable to the inclusion in interest expense of a pro-rata share of origination and other closing related fees from the six-month senior secured credit facility that began May 3, 2013.

CRITICAL ACCOUNTING POLICIESAND ESTIMATES

Preparation of our consolidated financial statements requires us to make significant estimates and judgments to develop the amounts reflected and disclosed in the consolidated financial statements. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

We believe our accounting policies specific to our revenue recognition, accrued claims payable, premium deficiencies and claims expense, and income taxes are critical to the preparation of our consolidated financial statements.

Revenue recognition. The majority of our managed care activities are performed under at-risk arrangements pursuant to terms of agreements primarily with health plans to provide contracted behavioral healthcare and pharmacy management services to subscribing members. Revenue under these agreements is earned continuously over time regardless of services actually provided and, therefore, is recognized monthly based on the number of qualified members. The information regarding qualified members is supplied by our clients,employees and we review member eligibility records and other reported information to verify its accuracy and determine the amount of revenue to be recognized. The remainingmonthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of our revenues is earned and recognized as services are delivered on a non-risk basis.

Accrued claims payable.Claims expense, a major component of cost of care, is recognized in the period in which an eligible plan member actually receives services and includes incurred but not reported (“IBNR”) claims. We contract with various healthcare providers including hospitals, physician groups and other licensed behavioral healthcare professionals either on a discounted fee-for-service or a per-case basis. We determine that a member has received services when we receive a claim within the contracted timeframe with all required billing elements correctly completed by the service provider. We then determine whether the member is eligible to receive the service, the service provided is medically necessary and is covered by the benefit plan’s certificate of coverage,$845,340. Both PVMS and the service is authorized by one of our employees, if required. If all of these requirementsBank are met,seeking guidance from the claim is entered into our claims system for payment.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

The accrued claims payable liability represents the estimated ultimate net amounts owed for all behavioral healthcare services provided through the respective balance sheet dates, including estimated amounts for claims IBNR. We have used the same methodology and assumptions for estimating the IBNR portion of the accrued claims liability for the last two years.

Our unpaid claims liability is estimated using an actuarial paid completion factor methodology and other statistical analyses. These estimates are subject to the effects of trends in utilization and other factors. Any significant increase in member utilization that falls outside of our estimates would increase claims expense and could adversely affect our ability to achieve and sustain improvements in profitability and positive cash flow. Although considerable variability is inherent in such estimates, we believe that our unpaid claims liability is adequate.

Whenever we believe it is probable that a future loss will be incurred under a managed care contract based on an expected premium deficiency and we are unable to cancel our obligation or renegotiate the contract, we record a loss in the amount of the expected future losses. We perform our loss accrual analysis on a contract-by-contract basis by taking into consideration various factors such as future contractual revenue, estimated future healthcare and maintenance costs, and each contract’s specific terms related to future revenue increases as compared to expected increases in healthcare costs. The estimated future healthcare and maintenance costs are based on historical trends and expected future cost increases. Our analysis at June 30, 2013 did not identify any loss contracts.

Accrued claims payable consists primarily of amounts established for reported claims and IBNR claims, which are unpaid through the respective balance sheet dates. Our policy is to record management’s best estimate of IBNR. The IBNR liability is estimated monthly using an actuarial paid completion factor methodology and is continually reviewed and adjusted, if necessary, to reflect any change in the estimated liability as more information becomes available. In deriving an initial range of estimates, we use an industry accepted actuarial model that incorporates past claims payment experience, enrollment data and key assumptions such as trends in healthcare costs and seasonality. Authorization data, utilization statistics, calculated completion percentages and qualitative factors are then combined with the initial range to form the basis of management’s best estimate of the accrued claims payable balance. However, estimating IBNR claims involves a significant amount of judgment by our management. The following are the principal factors that would have an impact on our future operations and financial condition:

Changes in the number of employee plan members due to economic factors;

Other changes in utilization patterns;

Changes in healthcare costs;

Changes in claims submission timeframes by providers;

Success in renegotiating contracts with healthcare providers;

Occurrence of catastrophes;

Changes in benefit plan design; and

The impact of present or future state and federal regulations.

The accrued claims payable ranges were between $11.6 and $11.7 million at June 30, 2013 and between $12.9 and $13.1 million at December 31, 2012. Based on the information available, we determined our best estimate of the accrued claims liability to be $11.7 million at June 30, 2013 and $13.1 million at December 31, 2012. Our accrued claims liability at June 30, 2013 and December 31, 2012 includes approximately $9.7 million and $9.8 million, respectively, of submitted and approved but unpaid claims and $1.9 million and $3.3 million for IBNR claims, respectively. A 5% increase in assumed healthcare cost trends from those used in our calculations of IBNR at June 30, 2013 could increase our claims expense by approximately $23,000. Actual claims incurred could differ from estimated claims accrued.

Income taxes. Computing our provision for income taxes involves significant judgment and estimates particularly in relation to the realization of deferred tax assets from net operating loss carryforwards, uncertain income tax positions, and in estimating the probable annual effective income tax rates for interim financial reporting periods.

At June 30, 2013, we have federal net operating loss carryforwards of approximately $35.5 million, the deductibility of $29.1 million of which is presently limited under Section 382 of the Internal Revenue Code to approximately $361,000 annually due to recent changes in control of the Company. We are particularly vulnerable to additional changes in control in the near term due to probable future equity dilution or possible takeover resulting in further loss of our ability to utilize the remaining carryforwards pursuant to Section 382. In addition, as of June 30,

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

2013, the Company continues to be in a deficit position. Based on this evidence, and the uncertaintySmall Business Administration as to our abilityhow to continue as a going concern, we concluded that atresolve this time,dispute. Until resolved, it is likely that this account will remain frozen.

During the Company’s deferred tax assets, which relate primarilyperiod we continued toward our goal to be able to uplist our Common Stock to another trading platform. Among the federal net operating losses, willactions is our attempt to reduce our stockholder’s deficiency by, among, other things, being able to convert a large portion of our corporate debt to equity. For the nine months ended September 30, 2020, $3,802,213 of debt plus accrued interest was converted into 40,417,682 shares of Common Stock. All of the holders of the converted debt agreed, subject to several different conditions, to a one year lock-up from publicly offering the shares. The primary condition being to not be realizable withinpublicly sell the carryforward period. Accordingly,shares until the Company continuesearlier of (i) one year from the date of the exchange, or (ii) until the shares are tradable on the NASDAQ or comparable national exchange. The other condition for a block of 14,584,350 shares received in an exchange has the lock-up as the earlier of one year or such time as our Common Stock has an average trading volume of no less than 500,000 shares for 30 consecutive trading days.

Subsequent Events

Subsequent to maintain an effective 100% valuation allowance against the balance of these deferred tax assets at this time. Our judgments regarding future taxable income may change due to many factors, including changes in operating results from changing economic or market conditions, or changes in tax laws, operating results or other factors.

RECENT ACCOUNTING PRONOUNCEMENTS

No recent accounting pronouncements have beenSeptember 30, 2020, we issued that are not yet effective and that have not been early adopted that, in our opinion, have a significant effect on our consolidated financial statements in future periods.

SEASONALITYOF BUSINESS

Historically, we have experienced increased member utilization during the months of March, April and May and consistently low utilization by members during the months of June, July, and August. Such variations in member utilization affect our costs of care during these months, having a generally positive impact on our operations during June through August and a negative impact from March through May.

LIQUIDITYAND CAPITAL RESOURCES

At June 30, 2013, we had a working capital deficiency of approximately $25.3 million and a stockholders’ equity deficiency of approximately $25.2 million resulting from a history of operating losses. We were unable to repay our 14% seniorconvertible promissory notes in the total principal amount of approximately $1.8 million on the maturity date of April 15, 2013. However, as of June 30, 2013, we have executed agreements to extend the maturity date for approximately $1.7 million$60,000. All of the notes to April 15, 2014. We are currentlydebt matures in discussions with the holders2021 and has a stated interest rate of the remaining senior notes and do not anticipate difficulty in completing extension agreements. In addition, we were not able to repay a $1 million loan due May 8, 2013. As of August 14, 2013, past due principal and interest totaled approximately $6.7 million, of which $4.8 million was owed to a related party who had not provided the Company with formal notice of default.

Our ability to continue as a going concern will be dependent upon the success of management’s plans, as set forth in the following paragraphs,12% and is subject to significant uncertainty. In their report on our most recent audited financial statements as of and for the year ended December 31, 2012, our independent auditors expressed substantial doubt as to our ability to continue as a going concern. Except for its consideration in establishing our valuation allowance for deferred tax assets, and an impairment write-down of goodwill taken in 2012, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.unsecured.

Revolving Credit Facility Agreement

On May 3, 2013, we entered into a Senior Secured Revolving Credit Facility Agreement that will allow us to borrow up to $5,000,000 to fund our general working capital needs. On the closing date, our current maximum allowable amount to borrow was $1,000,000. Increased borrowing amounts above the $1 million are subject to the sole and absolute discretion of the lender. Our initial $1,000,000 draw on the credit facility less transaction expenses of approximately $116,000 occurred May 3, 2013. As of August 8, 2013, our current outstanding balance on the credit facility is approximately $800,000 and there is currently no availability to draw additional funds on the credit facility. The credit facility is guaranteed by the current and future assets of CompCare and its subsidiaries, withPART II-OTHER INFORMATION

Item 1. Legal Proceedings

With the exception of the matter set forth below, all of the legal proceedings for the nine-month period ended September 30, 2020, are disclosed in our Puerto Rico subsidiary. Borrowingsannual report on Form 10-K filed on April 9, 2020. On September 4, 2020, in a matter entitled Dr. Jerry Katzman v. Comprehensive Care Corporation n/k/a/ Advanzeon Solutions, Inc. a receiver was appointed for Advanzeon Solution, Inc. ( the “Company”). The order granting the Plaintiff’s motion for appointment of a receiver was issued in the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County Florida, Case number 12-002570-Division L. The name of the receiver is Burton W. Wiand.

On September 7, 2020, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, Case number 8:20-bk-6764. Also, on September 7, 2020, the Company filed a Notice of Case Under Chapter 11 of the United States Bankruptcy Code and Notice of Automatic Stay with the Circuit Court of the 13th Judicial District in and for Hillsborough County, Florida.

The Company will continue to operate its business as “debtor-in possession” under the credit facility will bear interest at 12%, payable weekly. The credit facility will mature on November 3, 2013, at which time we may request an extensionjurisdiction of the maturity date for an additional six-month period provided that we are not in default in any respect, which, however, may be accepted or rejected by the lender in its sole discretion.

The credit facility agreement contains financial covenants such as, but not limited to, minimum revenues, positive earnings before interest, tax, depreciationBankruptcy Court and amortization expenses, and loan-to-value ratio. The agreement also specifies events of default and related remedies, including acceleration and increased interest rates following an event of default. In the event of a default by the Company, the lender may convert all or any portion of the outstanding principal, accrued but unpaid interest and other sums payable under the note into shares of our common

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

stock at a price equal to (i) the amount to be converted, divided by (ii) 85% of the lowest daily volume weighted average price of our common stock during the five business days immediately prior to the conversion date. The note or any portion thereof may also be converted in a likewise manner with the consent of the Company. As consideration for investment banking and advisory services provided to us by the lender, we issued 1,470,588 shares of our common stock to the lender as a fee, which in accordance with the termsapplicable provisions of the Agreement, was equivalent to $125,000.

Debt Modifications

On May 21Bankruptcy Code and June 18, 2013, we reached agreement with five holders of our senior promissory notes aggregating approximately $0.4 million of principal to extend the maturity dateorders of the notes from April 15, 2013Bankruptcy Court.

Subject to April 15, 2014. In connection withcertain exceptions under the renewals we issuedBankruptcy Code, the filing of the Company’s Chapter 11 petition automatically stayed the continuation of most legal proceedings or filing of other actions against the Company or on behalf of the Company for their property to recover, collect, or secure a total of 194,688 shares of our common stockclaim arising prior to the holders as partial payment of interest and fees owed as of April 15, 2013.

On May 13, 2013, we executed an agreement with a holder of approximately $1.3 million of our senior promissory notesPetition Date or to extend the maturity dateexercise control over property of the notes from April 15, 2013Company, unless or until the Bankruptcy Court modifies or lifts the automatic stay as to April 15, 2014. We also agreed to extendany such claim. Notwithstanding the term of approximately 5.2 million warrants that had been issued at the time the notes were issued in April 2010 for an additional two years, such that the warrants will now expire in 2017. In conjunction with the renewal, we issued 774,391 shares of our common stock to the lender relating to 50%general application of the interest and fees owed as of April 15, 2013.

On March 15, 2013, we executed an agreement with a creditorautomatic stay described above, government authorities may determine to modify the terms of a previously matured but unpaid promissory note in the amount of $1.4 million. Under the modified terms of the note, the maturity date was extended from February 28, 2013 to January 31, 2014 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. In addition, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was reset from $0.44 to $0.22. We also assigned a customer receivable (see Note 2 “Accounts Receivable”) and a potential arbitration recovery to the creditor as a source of future repayment of a second loan from the creditor in the amount of $625,000 that matured May 14, 2013 and a $75,000 loan from an individual related to the creditor, also due on May 14, 2013. By agreement with the creditor on May 8, 2013, the maturity date of the $625,000 loan was extended to July 15, 2013 and the conversion price at which the note may be converted into our common stock was reduced to $0.125 from $0.25. Additionally, the exercise price of a warrant to purchase our common stock issued in conjunction with the note was decreased from $0.44 to $0.22. The note was not repaid on its July 15, 2013 due date and is currently the subject of ongoing resolution negotiations. The $75,000 loan from the individual related to the creditor was repaid on May 6, 2013.

Need for Additional Financing

Our existing capital may not be sufficient to meet our cash needs. We expect that with:

i. our new Senior Secured Revolving Credit Facility;

ii. existing customer contracts;

iii. collection of receivables;

iv. extension of vendor payments;

v. the addition of significant new pharmacy management contracts that we have reason to believe will be obtained through:

(a)the expansion of our pharmacy management sales force;

(b)the signing of an agreement with a national leader in pharmacy benefit management;

(c)the integration of care management and wellness programs;

(d)our ability to commit to saving our clients substantial sums of money on their pharmacy expenses, backed by a performance bond to be issued by a surety company;

(e)our CEO joining the Board of Directors of “America’s Agenda: Health Care for All,”

that the Company will have the best opportunity to sustain and grow current operations over the near term. We continue to look at various alternative sources of financing if operations cannot support our ongoing plan. Nevertheless, there can be no assurance that we will be able to achieve the growth expected from allactions brought under their regulatory or some of the above factors, nor find such financing in amounts or on terms acceptable to us, if at all, or that we will be able to achieve or sustain profitable operations and positive operating cash flows in the near term. While management believes that our current cash position will likely be sufficient to meet our current levels of operations in the short term, our ability to achieve our business objectives and continue as a going concern for a reasonable period of time may be dependent upon the success of our plans to obtain sufficient debt or equity financing, and, ultimately, to achieve profitable operations and positive cash flows from operations during 2013.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

[policy] powers.

 

Our primary internal source of liquidity on an on-going basis has been from operations, which consists of the monthly capitation payments we receive from our clients for providing managed care services. Based on historical experience, there is a high degree of certainty with respect to the reliability and timing of these payments from continuing contracts. However, the commencement of new contracts or the expiration of existing contracts, such as our major Puerto Rico contract that ended December 31, 2012, may cause our operational cash flow to vary significantly from period to period, which would require us to seek external sources of liquidity.

Our external sources of liquid funds consist primarily of the use of debt and equity instruments. Our ability to continue to borrow funds on a secured or unsecured basis cannot be predicted, nor can our ability to sell shares of our common stock in private placement offerings. With the exception of contracted maturities of debt, there are no other future liquidity demands due to known commitments or events. We do not have any off-balance sheet financing arrangements. The duration of our borrowings has typically ranged from one week to three years, with stated interest rates ranging from 7% to 24%. Certain of the loans have contained features such as the ability to convert all or a portion of the loan into our common stock, or have had a detachable warrant for the future purchase of our common stock typically issued in conjunction with the loan, or both.

As evident in our statement of cash flows, during the six months ended June 30, 2013, our cash balance increased by $325,000 due primarily to collections of receivables, receipts from our revolving credit facility, from cost reduction initiatives or otherwise managing our cash outflows related to our costs, and from delaying payments to providers and other creditors, sometimes causing defaults in our obligation and sometimes negotiating successfully for extended terms. We also repaid existing debt, including certain capitalized leases, to the extent of $574,000.

ITEM 3. QUANTITATIVEAND QUALITATIVE DISCLOSURES ABOUT MARKET RISKItem 1A. Risk Factors

As a smaller reporting company as defined by Rule 229.10(f)(1) of the Exchange Act, we are not required to provide the information under this item.

ITEM 4. CONTROLSAND PROCEDURES

 

(a)Evaluation of Disclosure Controls and Procedures

Our management, withSee the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer along with the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

(b)Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary conduct of our business, we are subject to periodic lawsuits and claims. Although we cannot predict with certainty the ultimate resolution of lawsuits and claims asserted against us, we do not believe that any currently pending legal proceedings to which we are a party could have a material adverse effect on our business, or our future results of operations, cash flows or financial condition except as described below:

(1)

We initiated an action against Jerry Katzman, a former director, in July 2009 alleging that Mr. Katzman fraudulently induced us to enter into an employment agreement and, alternatively, that Mr. Katzman

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

breached that alleged employment agreement and was rightfully terminated. In September 2010, the matter proceeded to a trial by jury. The jury found that Mr. Katzman did not fraudulently induce CompCare to enter into the contract but also found that Mr. Katzman was not entitled to damages. On defendant’s motion to amend the verdict due to inconsistency, the trial court set aside the jury verdict and awarded Mr. Katzman damages of approximately $1.9 million. The Company appealed the lower court’s decision and posted a collateralized appeal bond for approximately $1.9 million. On February 14, 2013, the 11th Circuit Court of Appeals of the State of Florida reversed the lower court’s judgment which was in favor of Katzman. The decision of the appellate court also reverses the lower court’s award of attorney’s fees previously awarded to Katzman. As a result of the Court of Appeals reversal, the Company’s need to maintain appellate bonds in the aggregate amount of $1.9 million has been eliminated. The appellate court also taxed appellate costs in favor of CompCare against Katzman in the amount of $76,554. In addition, the Company holds a judgment against Katzman for approximately $1.3 million. The Company intends to pursue collection of this judgment.

(2)On March 2, 2012, a former health plan client in Missouri instituted an arbitration proceeding against us relating to allegations that we breached our obligation to pay claims submitted to us for payment. The amount demanded is approximately $2 million. We have filed a counter claim for breach of contract and tortious interference in an amount between $500,000 and $1 million. The parties have now completed document production. We intend to vigorously defend against the claims asserted in the arbitration demand.

(3)

On February 7, 2011, a health care provider, Oceans Healthcare, LLC, filed suit in the 19th Judicial District Court for the state of Louisiana claiming breach of contract in that we failed to pay claims submitted to us for payment. On January 14, 2013, the Court granted a motion to add six additional plaintiffs to the Oceans suit. The parties are demanding in excess of $2 million. The litigation is currently in the discovery stage. We intend to vigorously defend against the litigation.

(4)On May 30, 2013, a former health plan client in Michigan instituted an arbitration proceeding against us relating to its allegations that we breached our obligation to pay claims submitted to us for payment. The amount demanded is in excess of $5 million. The parties are in the process of selecting an arbitrator to hear the dispute. We intend to vigorously defend against the claims asserted in the arbitration demand.

(5)On August 10, 2012, we filed an arbitration demand against a former client in Puerto Rico. The Company believes that it is owed approximately $2.0 million. A hearing date is currently scheduled in October 2013.

Management believes that the Company has made adequate provision for any estimated probable losses, including legal defense costs, from the litigation described above.

ITEM 1A. RISK FACTORS

The risk factorsRisk Factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, have not changed materially.2019.

ITEMItem 2. UNREGISTERED SALESOF EQUITY SECURITIESAND USEOF PROCEEDSUnregistered Sales of Equity Securities and Use of Proceeds

During

With the exception of the matter set forth below, the sale of unregistered securities for the nine-month period May 21, 2013 through August 14, 2013,ended September 30, 2020 were disclosed in our annual report on Form 10-K filed on April 9, 2020.

On April 15, 2020, we issued sharesa convertible promissory note (the “Note”) in the principle amount of common stock$109,180 with an original issue discount of $6,180. The Note matures on October 15, 2021, and warrants to purchasethe interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On April 21, 2020, we issued a total of 14,584,350 shares of our common stock in private placements not involving a public offeringexchange for $2,916,869 of our Senior Debt and accrued interest to seven holders of the Debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as follows:amended.

 

On May 31, 2013,April 21, 2020, we issued an aggregatea total of 958,5471,327,252 shares of our common stock as payment of $95,855 of past due interest and amendment fees to three holdersin exchange for $265,450 of our senior promissory notes who had agreedconvertible debt and accrued interest to renew their notes for an additional year.the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

 

On June 3, 2013,April 21, 2020, we issued 100,000a total of 2,156,515 shares of our common stock to a vendor in exchange for website design$431,303 of our convertible debt and maintenance services valued at $6,800.accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

 

On June 25, 2013,May 13, 2020, we issued a warrantconvertible promissory note in the principle amount of $50,000 to purchase 10,000an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock to a vendor. The warrant, which expires June 2016, was vested in full at issuance and can be exercised at a per share price equal to the lesser of $0.25 per share.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

On June 26, 2013, we issued an aggregate of 10,531 shares(i) 15% below the average daily closing price of our common stock asfor the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of $1,053The Receivership of past due interestUniversal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to two holders of our senior promissory notes who had agreed to renew their notes for an additional year.

On July 15, 2013, we issued two warrants that may be used to purchasethe purchaser a total of 2,000,000 shares of our common stock. The warrants were issued to two consultants in lieu of cash compensation for marketing services. The warrants, which expire in July 2016, were vested in full at issuance and can be exercised at a price of $0.25 per share.

On July 25, 2013, we issued a three yearfive-year warrant to purchase 300,000100,000 shares of ourthe Company’s common stock at an exercise price of $0.25 to a consultant in lieu of cash compensation for marketing services. One-third of the shares obtainable with the warrant vested at issuance. The remaining shares vest evenly at 12 and 24 months after the issuance date.$0.15 per share.

 

On July 26,May 15, 2020, we issued 571,400a total 1,263,745 shares of our common stock to an individualin exchange for $139,012 of our convertible debt and two companies as payment of $60,000 of fees relatedaccrued interest to the Senior Secured Revolving Credit Facility, under which we borrowed $1 million on May 3, 2013.

Based on certain representations and warrantiesholder of the recipients referenced above, wedebt. We relied on Section 3(a)(9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 4,284,565 shares of our common stock in exchange for $471,302 of our convertible debt and 4(2)accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 7,210,168 shares of our common stock in exchange for $793,118 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 18, 2020, we issued a total 700,751 shares of our common stock in exchange for $77,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 21, 2020, we issued a total 502,434 shares of our common stock in exchange for $55,268 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 22, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 25, 2020, we issued a total 319,627 shares of our common stock in exchange for $35,159 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 25, 2020, we issued a total 333,824 shares of our common stock in exchange for $36,721 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 26, 2020, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

 On May 26, 2020, we issued a total 781,206 shares of our common stock in exchange for $85,933 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 28, 2020, we issued a total 884,555 shares of our common stock in exchange for $97,301 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 29, 2020, we issued a total 937,116 shares of our common stock in exchange for $103,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 1, 2020, we issued a convertible promissory note (the “Note”)in the principle amount of $56,180 with an original issue discount of $3,180. The Note matures on June 1, 2021, and the interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On June 1, 2020, we issued a total 1,024,189 shares of our common stock in exchange for $112,661 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 668,797 shares of our common stock in exchange for $73,568 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 603,987 shares of our common stock in exchange for $66,438 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 12, 2020, we issued a total 1,564,245 shares of our common stock in exchange for $172,067 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 18, 2020, we issued a total 504,957 shares of our common stock in exchange for $55,545 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 21, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 02, 2020, we issued a total 765,399 shares of our common stock in exchange for $84,194 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On July 22, 2020, we issued a convertible promissory note (the “Note”)in the principle amount of $56,180 with an original issue discount of $3,180. The Note matures on July 1, 2021, and the interest rate is 22 %. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On September 30, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.04. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.04 per share.

All of the convertible promissory notes listed above were issued to accredited investors, as that term is defined under the Section 501 of Regulation D, promulgated under the Securities Act of 1933, as amended. The warrants issued in connection with the promissory notes all have a cashless exercise feature.

On March 22, 2020, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On March 31, 2020, we issued 169,551 warrants to our Chief Executive Officer in lieu of 2020 first quarter salary. The warrants have a term of five years and an exercise price of $0.39 per warrant.

On April 14, 2020, we issued 96,058 warrants to a promissory note holder, an accredited investor, in lieu of interest. The warrants have a term of five years and an exercise price of $0.19 per warrant. The warrant has a cashless feature.

On April 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 101,599 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 230,630 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 146,811 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,589,044 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 368,804 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,589,044 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,095,253 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 25, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 10, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 11, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 3, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 6, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 8, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 8, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 10, 2020, we issued 200,000 warrants to our consultant. The warrants have a term of three years and an exercise price of $0.35 per warrant.

On June 11, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 14, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 20, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 22, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 27, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 01, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 01, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 01, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 01, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 06, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 25, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On August 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On August 31, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On September 25, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

We relied on Section 4 (2) of the Securities Act of 1933, as amended (the “Securities Act”)and or Section 501 of Regulation D promulgated under said Act as applicable, for an exemption from the registration requirements of the Securities Act. The shares purchased have not been registered under the Securities Act and may not be sold in the United States absent registration or an applicable exemption from registration requirements.under the Act.

ITEMItem 3. DEFAULTSUPON SENIOR SECURITIESDefualts upon Senior Securites

None.

Item 4. Mine Safety Disclousures

None.

Item 4T. Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2020. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our CFO concluded that, as of September 30, 2020, our internal controls over financial reporting were not optimally effective in the specific areas described in the paragraphs below.

As of August 14, 2013, past due principal and interest totaled approximately $6.7 million, of which $4.8 million was owed to a related party who had not providedSeptember 30, 2020, our CFO identified the Company with formal notice of default. We are currentlyfollowing specific material weaknesses in negotiations with certain of the holders to resolve the payment defaults.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

ITEM 6. EXHIBITSCompany’s internal controls over its financial reporting processes:

 

Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.

EXHIBIT
NUMBER

 

DESCRIPTION

 4.25Representative with Financial Expertise – For six-month period ended June 30, 2020, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.

As a result of our retaining the services of an Outside Accountant in January 2018 and appointing an internal Company employee to interface with the Outside Accountant, we have instituted the following policies and procedures designed to address the material weaknesses cited above.

All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.
 Loan Extension Agreement dated May 8, 2013 between the Company and Sherfam, Inc., incorporated by reference to Exhibit 4.25 to our Quarterly Report on Form 10-Q dated March 31, 2013 and filed May 20, 2013.
 4.26Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment).
 Second Note Modification Agreement dated May 13, 2013 between the Company and Lloyd I. Miller, incorporated by reference to Exhibit 4.26 to our Quarterly Report on Form 10-Q dated March 31, 2013 and filed May 20, 2013.
 4.27Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.
 Revolving Convertible Promissory Note dated May 3, 2013 between the Company and TCA Global Credit Master Fund, LP, incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated May 3, 2013 and filed May 9, 2013.
All bank accounts are reconciled monthly.
10.20 Senior Secured Revolving Credit Facility Agreement dated March 31, 2013 between the Company and TCA Global Credit Master Fund, LP, incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated May 3, 2013 and filed May 9, 2013.
Financial Statements are prepared and reviewed monthly.

The Company plans to further augment its addressing of material weaknesses, on an as-needed basis, by hiring additional accounting personnel once its initial corrective steps have been fully implemented, tested and found to be effective.

Item 5. Other Information

None.

Item 6. Exhibits

Documents filed as part of this Report.

Exhibit 31.1 Advanzeon Solutions, Inc. CEO Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2 Advanzeon Solutions, Inc. CFO Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1 Advanzeon Solutions, Inc. CEO Certification of Chief Executive Officerpursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2 Advanzeon Solutions, Inc. CFO Certification of Chief Financial Officerpursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101The following materials from Comprehensive Care Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, formatted in eXtensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements, tagged as blocks of text. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 COMPREHENSIVE CARE CORPORATIONAdvanzeon Solutions, Inc.
 Registrant
August 14, 2013 
Date: September XX, 2021By:/s/ Clark A. Marcus
By

/s/     CLARK A. MARCUS        

 Clark A. Marcus,
 Chief Executive Officer and Chairman
 
Date: September XX, 2021By:/s/ Arnold B. Finestone
 (Principal Executive Officer)Arnold B. Finestone,
By

/s/    ROBERT J. LANDIS        

Robert J. Landis
 Chief Financial Officer and Chief Accounting Officer
(Principal Financial and Accounting Officer)

 

2632